Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative

Sameer Kumar Malladi[1], Unnatiben Rajeshbhai Patel[2], R S Rajmani[1], Randhir Singh[2], Suman Pandey[2], Sahil Kumar[3], Sara Khaleeq[1], Savitha Gayathri[1], Debajyoti Chakraborty[1], Parismita Kalita[1], Ishika Pramanick[1], Nupur Agarwal[2], Poorvi Reddy[2], Nidhi Girish[2], Aditya Upadhyaya[2], Mohammad Suhail Khan[1], Kawkab Kanjo[1], Madhuraj Bhat[2], Shailendra Mani[4], Sankar Bhattacharyya[4], Samreen Siddiqui[5], Akansha Tyagi[5], Sujeet Jha[5], Rajesh Pandey[6], Shashank Tripathi[7,8], Somnath Dutta[1], Rajesh P. Ringe*[3], Raghavan Varadarajan*, [1]

[1] Molecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India

[2] Mynvax Private Limited, ES12, Entrepreneurship centre, SID, Indian Institute of Science, Bengaluru, India

[3] Virology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39-A, Chandigarh 160036, India

[4] Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Gurugram-Faridabad Expressway, Faridabad-121001

[5] Max Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare, Delhi-1100017, India

[6] INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi-110007, India

[7] Department of Microbiology & Cell Biology, Indian Institute of Science, Bengaluru 560012, India

[8] Centre for Infectious Disease Research, Indian Institute of Science, Bengaluru 560012, India

* Corresponding authors: Rajesh Ringe (rajeshringe@imtech.res.in), Raghavan Varadarajan (varadar@iisc.ac.in).

Correspondence:
Prof. Raghavan Varadarajan
Molecular Biophysics Unit,
Indian Institute of Science, Bangalore
Karnataka, India -560012
Email: varadar@iisc.ac.in
Phone: +91-80-22932612, FAX: +91-80-23600535

Abstract

The Receptor Binding Domain (RBD) of SARS-CoV-2 is the primary target of neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to a heterologous, poorly immunogenic disulfide linked trimerization domain derived from cartilage matrix protein. The protein was expressed at a yield of ~80-100 mg/liter in transiently transfected Expi293 cells, as well as in CHO and HEK293 stable cell lines, and formed homogeneous disulfide-linked trimers. When lyophilized, the trimer possessed remarkable functional stability to transient thermal stress of upto 100 °C and was stable to long term storage of over 4 weeks at 37 °C unlike an alternative RBD-trimer with a different trimerization domain. Two intramuscular immunizations with a human-compatible SWE adjuvanted formulation, elicited antibodies with neutralizing titers in guinea pigs and mice that were 25-250 fold higher than the corresponding values in human convalescent sera. Against the B.1.351 South African variant, neutralization titers for RBD trimer and human convalescent sera were ~ three-fold and greater than fourteenfold lower respectively. RBD was also displayed on a designed ferritin-like Msdps2 nanoparticle but this showed decreased yield and immunogenicity relative to trimeric RBD. Trimeric RBD immunized hamsters were protected from viral challenge. The excellent immunogenicity, thermotolerance, and high yield of such trimeric RBD immunogens suggest that they are a promising modality to combat COVID-19.

Keywords: glycosylation, thermostable, oligomerization, variant of concern

The Coronavirus infectious disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 [1,2] has led to ~158.6 million infections and ~3.3 million deaths worldwide as on 13th May, 2021 [3]. India is currently in the throes of a debilitating second wave, with the highest daily infection rate in the world. The viral spike glycoprotein is the most abundant protein exposed on the viral surface and the primary target of host elicited humoral immune responses [4–15]. Thus, there are a large number of COVID-19 vaccine candidates in various stages of development, with ~ 11 candidates already granted emergency use authorisation. However, all of these are required to be stored either refrigerated or frozen. There is thus an unmet need for efficacious vaccines that can be stored for extended periods at room temperature. In addition, there are recent reports of new strains of the virus with enhanced transmissibility and immune evasion [16,17]. This emphasizes the urgent need to develop vaccine formulations that elicit high titers of neutralizing antibodies to buffer against viral sequence variation [18–20]. Spike glycoprotein, like various Class I viral surface glycoproteins, assembles as a trimer with each protomer composed of the surface exposed S1 and membrane anchored S2 subunit [21]. The S1 subunit consists of four independently folding domains: N-terminal domain (NTD), Receptor binding domain (RBD), and two short domains (SD1 and SD2) connected by linker regions [4,5,22]. The receptor binding domain (RBD) contains the receptor binding motif (residues 438-505) that facilitates interaction with the ACE2 receptor. Subsequent fusion or endocytosis is mediated by the fusion peptide that constitutes the N-terminal stretch of the S2 subunit [21]. It is now well understood that the majority of neutralizing antibodies in both natural infection and vaccination target the RBD [8,9,11,12,23–28]. Thus, various groups are involved in designing RBD-based immunogens [29–40]. We have previously designed a glycan engineered RBD derivative that was highly thermotolerant and induced moderate titers of neutralizing antibodies [37]. Monomeric versions of immunogens elicit lower binding and neutralizing antibodies than multimeric versions [29,37,40,41]. Potential strategies to improve neutralizing antibody titers include fusions containing

repetitive antigenic proteins, Fc fusion based dimerization, nanoparticle design and display strategies, and VLP based display platforms [31,32,38–43]. While effective, several display strategies lead to significant antibody titers against the display scaffold or oligomerization motif, such antibodies might either show undesirable side effects in a small fraction of individuals or direct the response away from the intended target after repeated immunizations. In an alternative strategy, we fused our previously described thermotolerant RBD [37] to a trimerization motif, namely a disulphide linked coiled-coil trimerization domain derived from human cartilage matrix protein (hCMP), to the N-terminus of mRBD. This trimerization domain is expected to be less immunogenic in small animals due to its homology with the corresponding ortholog, than other widely used trimerization domains of bacterial or synthetic origin such as foldon or IZ [44]. In order to compare trimeric RBD with nanoparticle displayed RBD, we also displayed RBD on the surface of ferritin like nanoparticles, employing SpyCatcher-SpyTag technology [45,46]. hCMP-mRBD expressed as homogenous trimers, possessed comparable thermal stability profiles to the corresponding monomer [37] and remained functional after over 4 weeks upon lyophilization and storage at 37 °C. The trimeric RBD is highly immunogenic in mice and guinea pigs when formulated with SWE adjuvant. SWE is equivalent to the widely used, clinically approved, MF59 adjuvant [47]. Oligomerization increased neutralizing antibody titers by ~25-250 fold when compared with the titers in human convalescent sera, providing a proof of principle for the design strategy. Further the hCMP-mRBD protected hamsters from viral challenge, and immunized sera from mice and guinea pigs neutralized the rapidly spreading B.1.351 viral variant with only a three-fold decrease in neutralization titers. Stable *CHO* and *HEK293* cell lines expressing hCMP-mRBD were constructed and the corresponding protein was as immunogenic, as the protein expressed from transient transfection. Nanoparticle displayed RBD was expressed at lower yield and did not confer any apparent advantage in immunogenicity relative to trimeric RBD. The very high

thermotolerance, enhanced immunogenicity, and protection from viral challenge suggest that this trimeric mRBD with inter-subunit, stable disulfides, is an attractive vaccine candidate that can be deployed to combat COVID-19 without requirement of a cold-chain, especially in resource limited settings.

Results

Design of trimeric RBDs of SARS-CoV-2

We previously designed a monomeric glycan engineered derivative of the receptor binding domain termed mRBD (residues 332-532 possessing an additional glycosylation site at N532) that induced neutralizing antibodies in guinea pig immunizations [37]. It is known that oligomerization of native antigens can induce higher titers of binding and neutralizing antibodies [31,40,42,48–52]. We therefore fused mRBD to the disulfide linked trimerization domain derived from human cartilage matrix protein (hCMP) (residues 298-340). We have previously used this domain to successfully trimerize derivatives of HIV-1 gp120. These earlier derivatives were used to successfully elicit high titers of broadly reactive anti-gp120 antibodies in guinea pigs, and rabbits. In rhesus macaques when combined with an MVA prime, the formulation conferred protection against heterologous SHIV challenge, without apparent adverse effects [53–55]. We hypothesized that RBD fused to the hCMP trimerization domain (residues 298-340), would elicit higher neutralizing antibody titers relative to the corresponding monomer. In the closed state structure model of Spike-2P protein (PDB 6VXX, residues 332-532), the three RBDs are in the down conformation. We separated the coaxially aligned hCMP trimerization domain C-terminal residue 340, Cα plane from the RBD N-terminal Cα plane by ~22 Å to eliminate any steric clashes (Figure 1a). The distance between the hCMP C-terminus residue 340 and RBD N-terminus residue 332 was ~ 39.0 Å in the

modeled structure (Figure 1a). A fourteen amino acid linker L14 will comfortably span this distance. We employed the same trimerization domain-linker combination used in our previously described HIV-1 gp120 trimer design [56]. Thus, the trimeric hCMP-mRBD design consisted of the N-terminal hCMP trimeric coiled coil domain (residues 298-340) fused to the I332 residue of mRBD by the above linker, followed by the cleavable His tag sequence described previously [37] (Figure 1b). The hCMP trimerization domain leads to formation of covalently stabilized trimers crosslinked by interchain disulfides in the hCMP domain. This design is termed hCMP-mRBD and hCMP pRBD where the "m" and "p" signifies expression in mammalian or *Pichia pastoris* cells, respectively.

Further, we also designed trimeric RBD constructs (residues 332-532) by fusing hCMP and glycosylated IZ [44] synthetic trimerization domains at the C-terminus of RBD (Figure 1b). GlyIZ is a glycosylated version of the synthetic trimerization domain IZ. The glycosylation results in immunosilencing of the otherwise highly immunogenic IZ sequence [44]. These constructs were named mRBD-hCMP and mRBD-GlyIZ respectively (Figure 1b). Additionally, we constructed a SpyCatcher [45] fusion of mRBD by fusion of SpyCatcher [45] to the C-terminus of the mRBD. This construct is referred to as mRBD-SpyCatcher. These fusion constructs are expressed from transiently transfected mammalian cell culture platforms. A dodecameric self-assembling nanoparticle (MsDPS2) from *Mycobacterium smegmatis* was fused to SpyTag [45,46] by a 15 residue linker to aid in the complexation of nanoparticle with mRBD-SpyCatcher (Figure 1b). We have successfully employed the MsDPS2 nanoparticle to display trimeric influenza stem immunogens [57].

Figure 1. Design and characterization of trimeric mRBD. a. The design utilized the RBD (residues 332-532) from the closed state of the Spike-2P (PDB 6VXX) aligned coaxially with the hCMP trimerization domain, coordinates taken from the homolog CCMP (PDB:1AQ5, Chain 1.1). The N termini of mRBD are labelled as I332 and the hCMP trimerization domain C-termini are labelled as V340. The N, C termini Cα's form vertices of equilateral triangles. The N-terminal plane of RBD (I332) is separated from the C-terminal plane (V340) of the hCMP trimerization domain by ~22.1 Å to avoid steric clashes. The I332 terminus and V340 terminus are ~39 Å apart in the modelled structure and are connected by a 14-residue long linker. **b.** hCMP-mRBD consists of N-terminal hCMP trimerization domain fused to I332 of RBD by a linker (L14). mRBD-hCMP consists of the C-terminal hCMP trimerization domain fused to N532 of RBD by a linker (L5). mRBD-GlyIZ consists of a C-terminal GlyIZ trimerization domain fused to N532 of RBD by a linker (L5). MsDPS2-mRBD consists of the MsDPS2 nanoparticle fused to SpyTag covalently linked with mRBD-SpyCatcher. **c.** SEC elution profile of trimeric hCMP-mRBD. **d.** SDS-PAGE of purified mRBD and hCMP-mRBD in reducing and non-reducing conditions demonstrating formation of disulfide-linked trimers. **e.** SEC-MALS of purified hCMP-mRBD (MW: 110 ±10 kDa). The red, black and blue

profilesare of the molar mass fit, molar mass and refractive index (RI) respectively. **f.** nanoDSF equilibrium thermal unfolding of hCMP-mRBD. **g.** SDS-PAGE of purified mRBD-GlyIZ andmRBD-hCMP in reducing conditions. **h, i.** SEC elution profiles of mRBD-hCMP (H) and mRBD-GlyIZ (I). **j.** SDS-PAGE of purified MsDpS2-SpyTag, mRBD-SpyCatcher and the resulting MsDPS2-SpyTag-mRBD-SpyCatcher conjugate abbreviated MsDPS2-mRBD for simplicity. The black solid line, triangle without fill and red triangle correspond to MsDPS2- SpyTag nanoparticle, mRDS-SpyCatcher and MsDPS2-mRBD conjugate respectively. **k.** SPR binding of hCMP-mRBD, mRBD-hCMP, mRBD-GlyIZ and SEC purified complex MsDPS2-mRBD to immobilized ACE2. The curves from highest to lowest correspond to concentrations100 nM, 50 nM, 25 nM, 12.5 nM and 6.25 nM respectively for hCMP-mRBD, mRBD-hCMPand mRBD-GlyIZ. The curves for MsDPS2-mRBD correspond from highest to lowest concentrations of 10 nM, 5 nM, 2.5 nM and 1.25 nM respectively. ND*- No dissociation.

hCMP-mRBD forms homogenous, thermotolerant trimers

hCMP-mRBD was first expressed by transient transfection in Expi293F suspension cells, followed by single step metal affinity chromatography (Ni-NTA) and tag cleavage. The purified protein was observed to be pure and trimeric by reducing and non-reducing SDS-PAGE (Figure 1c, 1D). The protein exists as a homogenous trimer in solution and the molar mass was determined by SEC-MALS to be 110 ±10 kDa, consistent with the presence of nine glycosylation sites in the trimer (Figure 1c, 1e). Negative stain EM analysis confirmed the trilobed arrangement of RBD structure (Supplementary Figure S1). Trimeric hCMP-mRBD was observed to have comparable thermal stability (T_m: 47.6 °C) as monomeric mRBD (T_m: 50.3 °C) (Figure 1f) and bound both its cognate receptor ACE2 and a SARS-CoV-1 neutralizing antibody CR3022 with very high affinity (K_D <1nM) and negligible dissociation (Figure 1k, Supplementary Figure S2) [37].

The fusion constructs mRBD-hCMP and mRBD-GlyIZ were purified from transiently transfected *Expi293F* cells. mRBD-GlyIZ was observed to be more heterogeneous compared to hCMP-mRBD and mRBD-hCMP (Figure 1c, 1g, 1h, 1i). mRBD-hCMP showed negligible dissociation and bound ACE2 and CR3022 similar to hCMP-mRBD (Figure 1k,

Supplementary Figure S2). mRBD-GlyIZ bound ACE2 and CR3022 with a K_D of 3-5 nM (Figure 1k, Supplementary Figure S2). mRBD-SpyCatcher and MsDPS2-SpyTag were complexed in the ratio 1:3, the conjugation was confirmed by SDS-PAGE, and the nanoparticulate conjugate was purified by SEC (Figure 1j, Supplementary Figure S4). The SEC purified nanoparticulate mRBD bound ACE2 and CR3022 with high k_{on} ($>10^6$ M^{-1}s^{-1}) and negligible k_{off}, indicating formation of a functional MsDPS2-mRBD nanoparticle (Figure 1k, Supplementary Figure S2).

Figure 2. Characterization of trimeric hCMP-mRBD following transient exposure to elevated temperature and extended incubation at 37 °C. a. hCMP-mRBD in PBS at a concentration of 0.2 mg/ml was subjected to transient thermal stress for one hour and bindingstudies performed at 100nM. **b.** Lyophilized hCMP-mRBD was subjected to transient thermalstress for 90 minutes followed by reconstitution in water. **c.** hCMP-mRBD (0.2 mg/ml) in solution subjected to 37 °C incubation as a function of time (3-72 hr) **d.** Lyophilized hCMP- mRBD subjected to extended thermal stress at 4 °C and 37 °C for 2 and 4 weeks. 100nM of hCMP-mRBD was used as analyte. **e-f** Equilibrium thermal unfolding monitored by nanoDSF. **e.** hCMP-mRBD (0.2mg/ml) subjected to 37 °C incubation in 1xPBS for upto 72 hours. **f.** nanoDSF of lyophilized hCMP-mRBD

incubated for upto 4 weeks at 4 °C and 37 °C. The lyophilized protein was reconstituted in MilliQ grade water prior to thermal melt and SPR binding studies. The binding to ACE2-hFc was performed at 100nM. ACE2-hFc immobilized was 800RU. hCMP-mRBD is thus highly resistant to transient and extended thermal stress.

Thermal tolerance to transient and extended thermal stress is a desirable characteristic for deployment of vaccines in low resource settings in the absence of a cold-chain. hCMP-mRBD protein in solution was observed to retain functionality after 1 hour exposure to temperatures as high as 70 °C (Figure 2a). The lyophilized hCMP-mRBD was also observed to retain functionality to transient ninety-minute thermal stress upto 99 °C (Figure 2b). Further, the protein remained natively folded and at 37 °C retained functionality in solution upto three days, and for at least four weeks in the lyophilized state (Figure 2c, 2d, 2e, 2f). In contrast mRBD-GlyIZ showed substantially decreased ACE2 binding after one hour incubation at temperatures above 40 °C and lost ACE2 binding after lyophilization and resolubilization. (Supplementary Figure S3a, S3b)

Trimeric mRBD elicits high titers of neutralizing antibodies in mice and guinea pigs and protects hamsters from viral challenge

We assessed the immunogenicity of the previously described [37] monomeric mRBD and trimeric hCMP-mRBD adjuvanted with SWE, an AddaVax™ and MF59 equivalent adjuvant, in BALB/c mice. Animals were immunized intramuscularly at day 0, followed by a boost at day 21 [37]. Two weeks post boost, sera were assayed for binding and neutralizing antibodies. Trimeric hCMP-mRBD adjuvanted with SWE elicited 16-fold higher mRBD binding titers compared to monomeric mRBD (Figure 3a). Pseudoviral neutralization titers elicited by trimeric hCMP-mRBD were 45-fold higher (hCMP-mRBD GMT: 31706, mRBD GMT: 707, P = 0.008) compared to monomeric mRBD (Figure 3b). We compared the immunogenicity of hCMP-mRBD adjuvanted with AddaVax™ and SWE respectively. The mRBD binding titers

and pseudoviral neutralization titers were similar in both adjuvants, confirming their functional equivalence (Supplementary Figure S4a, S4b).

Next, we assessed the immunogenicity of trimeric, SWE adjuvanted hCMP-RBD derived from different expression platforms, namely CHO and Pichia stable cell lines (Figure 3c, Supplementary Figure S5). The binding titers were 12-fold higher in CHO derived hCMP-mRBD compared to hCMP-pRBD (P = 0·008) (Figure 3c, Supplementary Figure S5). CHO derived hCMP-mRBD (GMT: 24086) elicited high pseudoviral neutralizing titers compared to sera elicited by Pichia expressed hCMP-pRBD which showed negligible neutralization (P = 0·008) (Figure 3d, Supplementary Figure S5).

N-terminal trimerized mRBD derived from CHO cells (hCMP-mRBD GMT: 235253) elicited similar mRBD binding titers compared to C-terminal trimerized mRBD in SWE adjuvanted formulations (Figure 3c). The pseudoviral neutralization titer elicited by N-terminal trimerized hCMP-mRBD (GMT: 24086) is 3-fold (P = 0.0317) and 2-fold (P = 0.42) higher compared to C-terminal trimerized mRBD-hCMP (GMT: 7472) and mRBD-GlyIZ (GMT: 12505) respectively (Figure 3d).

MsDPS2-mRBD nanoparticle adjuvanted with SWE, elicited similar mRBD binding antibody titers compared to hCMP-mRBD (GMT: 235253) (Figure 3c) but ~4-fold (P = 0.008) lower pseudoviral neutralization titers (GMT: 24086 compared to MsDPS2-mRBD, GMT: 6181) (Figure 3d).

Figure 3. ELISA and pseudovirus neutralization with sera elicited at weeks 0, 3 after two immunizations with SWE adjuvant containing formulations. a, b. Immunization with mRBD (white panel) or hCMP-mRBD (gray panel) (n = 5 mice/group) **c-e** Immunizations with mRBD-hCMP, mRBD-GlyIZ or MsDPS2 nanoparticle displaying mRBD (n = 5 mice/group). Pseudoviral neutralization titers utilized pNL4-3.Luc. SARS-CoV-2 D614G Δ19. HCS: Human Convalescent Sera (n = 40). **e.** ELISA binding titer against scaffolds hCMP, GlyIZ trimerization domain, MsDPS2 SpyTag, and SpyCatcher. **f- j.** Pseudoviral neutralization titers against wildtype and pseudovirus with B.1.351 RBD mutations. The paired comparisons were performed utilizing the Wilcoxon Rank-Sum test in F-G. The black solid horizontal lines in each scatter plot represent Geometric Mean Titer (GMT). The pairwise titer comparisons were performed utilizing two- tailed Mann-Whitney test in A-E (* indicates P < 0.05, ** indicates P < 0.01, **** indicates P < 0.0001). **k.** Neutralizing antibody titers in mice (blue), in Human Convalescent Sera (HCS) (red) assayed in the identical assay platform, and their relative ratio (green). Values for a number of vaccine candidates being tested in the clinic or provided with emergency use authorizations are shown [58–71] and corresponding values for hCMP-RBD are boxed.

The hCMP trimerization domain and nanoparticle scaffolds can also elicit binding antibodies. The binding titers directed towards the Glycosylated IZ were measured by ELISA utilizing influenza HA stem fused to GlyIZ as the immobilized antigen and observed to be the lowest (GMT: 400), 5-fold lower compared to hCMP binding titers (GMT: 2111). The latter were estimated using hCMP V1cyc JRFL gp120 containing the same trimerization domain (Figure 3e)[48]. The MsDPS2-SpyTag and SpyCatcher titers are 111-fold (GMT: 44572, P = 0·0079) and 28-fold higher (GMT: 11143, P = 0.0079) compared to GlyIZ directed titers (Figure 3e) respectively.

We measured the ability of the anti-sera to neutralize pseudovirus containing the RBD mutations present in the isolate B.1.351 (K417N, E484K and N501Y). Sera elicited by hCMP-mRBD, mRBD-hCMP and mRBD-GlyIZ neutralized SA pseudovirus with 1.4-2.4 fold lower titers compared to Wt pseudovirus (P = 0.05-0.06) (Figure 3f, 3g, 3h). Nanoparticle MsDPS2-mRBD elicited sera neutralized the SA virus with 5.6-fold lower titers compared to Wt (Figure 3i). High titer Human convalescent sera (HCS) neutralized the SA virus with 14-fold lower titer (SA GMT: 59) compared to Wt (GMT: 845) (Figure 3j), and most HCS failed to neutralize the SA virus (Figure 3j).

We assessed the immunogenicity of hCMP-mRBD adjuvanted with AddaVax™ in guinea pig immunizations following prime (Wk 0) and, two boosts (Wk 3 and Wk 6). Both binding and neutralization titers were significantly enhanced following the second boost (Supplementary Figure S6a, S6b). Trimerization scaffold directed titers in guinea pigs showed only a marginal increase after the second boost (Supplementary Figure S6c). Sera collected after the second boost neutralized SA pseudovirus (GMT: 8252) with 4.3-fold lower titer compared to Wt (GMT: 35693) while corresponding sera from Spike-2P immunized animals showed a 15-fold drop (Supplementary Figure S6d, S6e). Unfortunately, sera after the first boost were not

available to assay against the SA pseudovirus. Importantly, both mice and guinea pigs did not elicit any binding antibodies to the L14 linker present in the immunogens.

Pseudoviral neutralization titers correlated well in two independent assay platforms performed with an identical set of sera and with live virus neutralization titers from a CPE based assay (Supplementary Figure S7). Additionally, we performed a dose sparing study involving 5 μg hCMP-mRBD adjuvanted with SWE. The mRBD binding titers were observed to be marginally higher compared to the 20 μg dose and pseudoviral neutralization titer were similar. (Supplementary Figure S8). Trimeric hCMP-mRBD elicited exceedingly high neutralizing antibodies in mice, compared to Human Convalescent Sera (HCS) titers assayed in the identical assay platform. Additionally, both the mice neutralizing antibody titers and their ratio relative to HCS neutralizing titers compared favorably with corresponding values for vaccine candidates being tested in the clinic or provided with emergency use authorizations (Figure 3k). For COVID-19 vaccines mice titers are predictive of those in humans [37].

To examine efficacy, we carried out a hamster immunization and challenge study. Hamsters were immunized with hCMP-mRBD at Wk 0, 3 and 6. The mRBD binding titers (GMT:18101) and neutralization titers (GMT: 1423) were lower than those observed in guinea pigs and mice (Figure 4a), neutralization titers remained unchanged between the first and second boost. The scaffold directed titers were $\sim 10^3$, consistent with the low sequence identity of hCMP (51%) with the hamster ortholog (Figure 4b). Following immunization, animals were challenged with replicative Wt virus. Two additional groups, namely unimmunized-unchallenged (UC) and unimmunized-virus challenged (VC) animals, acted as controls. Post infection, the immunized animals regained weight and showed markedly lower clinical signs (Figure 4c, 4d), lung viral titers (Figure 4e) and histopathology scores relative to the VC control group (Figure 4f-4j). The tissue sections show clear lung epithelial interstitial spaces and minimal immune cell infiltration in the immunized group compared to virus challenged group.

All animals remained healthy after the immunizations. We conclude that hCMP mediated trimerization of mRBD led to elicitation of robust binding and neutralizing antibodies considerably in excess of those seen in convalescent sera, that protected hamsters from high dose, replicative viral challenge.

Characterization of hCMP-mRBD expressed from permanent cell lines

Stable Chinese hamster ovary (CHO) and HEK293 suspension cell lines expressing the protein were constructed. Purified protein yields were 80-100 mg/liter, similar to those expressed in *Expi293* cells, and SDS-PAGE revealed the presence of disulfide linked trimers (Supplementary Figure S9). CHO expressed protein adjuvanted with SWE adjuvant has comparable immunogenicity in mice to transiently expressed protein (Figure 3a, 3b, 3c, 3d).

hCMP-pRBD protein was also expressed in the methylotrophic yeast *P. pastoris* at a purified yield of ~7mg/liter. As observed previously with monomeric RBD [37], the protein was more heterogeneous and formed high molecular weight aggregates unlike mammalian cell expressed proteins (Supplementary Figure S5a, Figure 1d and Supplementary Figure S9). In mice, formulations with the AddaVax equivalent adjuvant, SWE [72], elicited low mRBD and negligible neutralization titers after two immunizations (Supplementary Figure S5b, S5c).

Figure 4. Hamster Immunization and challenge studies with trimeric hCMP-mRBD. a. Hamsters (n = 4/group) were immunized at week 0, 3 and 6 with 20 µg of hCMP-mRBD adjuvanted with AddaVax™. **a.** At 14 days post boost, sera were assayed for ELISA binding titer against mRBD and pseudoviral neutralization titer utilizing pNL4-3.Luc. SARS-CoV-2 D614G Δ19. **b.** ELISA binding titer against scaffold hCMP. Post immunization, the hamsters were challenged intranasally with replicative SARS-CoV-2 virus (10^6 pfu/hamster) and monitored for **c.** Weight change. The pairwise titer comparisons were performed utilizing two-tailed student-t test (* indicates P < 0.05, ** indicates P < 0.01). **d.** Clinical signs **e.** Lung viral titer. Histopathology

scores including **f.** Lung pathology score **g.** Inflammation score **h.** Immune cell influx score **i.** Edema score. **j.** Histology of lung sections at varying magnifications (4X, 10X and 40X). Lung pathologies of Unchallenged control (UC), virus challenged and immunized animals. The virus challenged lung histology marked to identify 1. Bronchiolitis and bronchopneumonia, 2. Severe alveolar inflammation (leukocytic alveolitis), alveolar edema and congestion of parenchyma, severe blood hemorrhage and leakage of alveolar sacs, 3. perivascular inflammation and vascular congestion, 4. bronchial infiltration of immune cells with marked edema.

Discussion

There are currently multiple COVID-19 vaccines that have been given emergency use approval and others with encouraging Phase I data [66] are in advanced clinical trials. There remains a need for cheap, efficacious, COVID-19 vaccines that do not require a cold chain and elicit antibodies capable of neutralizing emerging variants of concern (VOC). Despite the extraordinarily rapid pace of vaccine development, there are currently many countries where not even a single dose has been administered. This will prolong the pandemic and promote viral evolution and escape [73]. It has also become clear that minimizing the extent of non SARS-CoV-2 derived immunogenic sequence in the vaccine is highly desirable. We previously designed a thermotolerant, monomeric, glycan engineered RBD (residues 332-532) that elicited neutralizing antibodies. In the present study we sought to improve the immunogenicity without negatively altering biophysical and antigenic characteristics of the designed immunogen by designing trimeric and nanoparticulate RBDs. Overall, trimeric hCMP-mRBD elicited higher binding and neutralizing antibodies in both mice and guinea pigs compared to monomeric mRBD. The best trimeric mRBD involved fusion with the hCMP trimerization domain at the N-terminus of mRBD. Relative to other trimerization domains such as foldon and GCN4 derivatives [32,65], this forms a trimer that is stabilized by intermolecular disulfides and hence will not dissociate, even at high dilutions. A fusion of hCMP with HIV-1 gp120 has been extensively tested in guinea pigs, rabbits and non-human primates as an HIV-1 vaccine candidate and showed promising immunogenicity without any apparent adverse effects [48,54,55].

This trimerization sequence has sequence identities with the corresponding ortholog of 81, 91 and 51% in mice, guinea pigs and hamsters, consistent with the low hCMP directed titers in guinea pigs. Thus, hCMP titers in humans are expected to be negligible, given 100% sequence identity with the host protein. Immunization studies in non-human primates with hCMP-mRBD will be shortly initiated to confirm this. In addition, fusion of the short disulfide forming stretch to the other trimerization domains is being carried out to examine the modularity of this motif. Like our previously described monomeric mRBD, hCMP-mRBD shows remarkable thermotolerance. Lyophilized hCMP-mRBD was stable to extended storage at 37 °C for over four weeks and to transient 90-minute thermal stress of upto 100 °C. In contrast, to the alternative GlyIZ trimerization sequence, the disulfide linked hCMP-mRBD was more homogeneous and thermotolerant, demonstrating that the latter feature is not a given for any multimeric RBD formulation. Mice were immunized with various trimeric and nanoparticle displayed RBD constructs (Figure 1) adjuvanted with SWE, a GMP grade adjuvant equivalent to MF59. MF59 has a long safety record of use in humans [47]. Trimerization of mRBD led to elicitation of about 40-fold higher mRBD binding and neutralizing antibodies compared to those elicited by mRBD immunizations in mice. No detectable antibodies were elicited against the short gp120 derived stretch present in the linker of hCMP-mRBD in either mice or guinea pigs. Neutralization titers produced are considerably in excess of those seen in patient derived convalescent sera by factors of ~25-250 folds in mice and guinea pigs respectively (Figure 3b, 3d, Supplementary Figure S7). In mice, the formulation induced higher binding and neutralizing antibodies compared to guinea pigs, presumably owing to various differences in the two host immune systems. Trimeric RBD bound ACE2-hFc receptor and the conformation specific antibody CR3022 [74] tightly, with undetectable dissociation (Figure 2e). Since neutralization assays differ in their relative sensitivity, in order to compare across studies, it is useful to examine the neutralization titers, relative to a panel of convalescent sera measure in

the same assay. Using this criterion the present titers compare favorably with those of many other formulations that have been tested in the mouse model, including several licensed COVID-19 vaccines. The neutralization titers elicited by the present trimeric RBD compare well with pseudoviral neutralization titers produced by a two dose immunization schedule of nanoparticle displayed RBD adjuvanted with AddaVax (IC_{50} GMT of 5 µg RBD-12GS-I53-50: 20000, corresponding IC_{50} GMT of human convalescent sera: 60, ~330 fold higher compared to HCS) and the Novavax Spike-2P adjuvanted with Matrix-M1 in mice (CPE_{100} GMT: 20000, CPE_{100} HCS GMT: 983, ~20 fold higher compared to HCS) [40,66]. Additionally, hCMP-mRBD elicited higher neutralizing titers than a 5 µg mRNA based RBD-foldon trimer vaccine construct BNT162b1 tested in mice (IC_{50} GMT: 753, HCS IC_{50} GMT: 94, ~8 fold higher compared to HCS) [65]. In contrast to recently described, highly immunogenic multi-component nanoparticle systems [39,40], the present single component, trimeric RBD might be easier to purify and manufacture and in our hands, nanoparticle display did not confer any significant benefit in immunogenicity over trimerization, whilst the former elicited considerably higher titers of scaffold directed antibodies. However, multicomponent as well as Spy-tagged nanoparticles do have the potential advantage of modularity and being able to display two or more antigens simultaneously. Trimeric RBD elicited sera neutralized B·1·351 pseudovirus with only a relatively small drop in neutralization titer compared to that seen in convalescent sera (Figure 3f-3j). This large drop in HCS has also been observed in other studies, for example it was observed [75] that 50% of convalescent sera showed complete loss of neutralization of B.1.351. In another recent study [76], a ten-fold drop in neutralization titers against B.1.351 was observed in sera from vaccines immunized with Pfizer-BioNtech and Moderna vaccines. Fortunately, other recent variants such as B·1·1·7 (UK) and B·1·617 do not show such high immune evasion [77]. Interestingly when compared with guinea pigs immunized with the Spike ectodomain, sera from animals immunized with hCMP-mRBD appear to show

a smaller decrease in neutralization titer against B.1.351 though more data are required to confirm this (Supplementary Figure S6 d-e). A recent study utilizing E2p nanoparticle display of Spike-2G (K986G, V987G)-ΔHR2 (E1150-Q1208) termed S2GΔHR2 employ two intraperitoneal immunizations led to elicitation of unaltered neutralization titer to the B.1.351 viral strain [78]. While encouraging, such an immunization route is unsuitable for mass vaccinations. Finally, the present trimeric RBD was safe and efficacious, protecting hamsters from viral challenge. In summary, the present study describes the design of a disulfide linked, highly expressed, homogenous, trimeric RBD immunogen that is stable to long term thermal stress, and induces robust neutralizing antibodies against SARS-CoV-2 with a modest decrease in titers against pseudovirus with the three mutations present in B.1.351. The availability of permanent cell lines for the immunogen now makes it possible to proceed with further clinical development of this highly immunogenic, thermotolerant and easily producible COVID-19 vaccine candidate.

Conclusion

We describe a thermotolerant, homogenous, intermolecular disulfide-linked, trimeric RBD that is highly expressed, immunogenic, and elicits sera which neutralize both wildtype and B.1.351 virus. This is an excellent candidate for future clinical development and deployment, is easily manufacturable at a large scale, and eliminates the requirement of a cold-chain.

Methods

Trimeric RBDs and antibody expression constructs

The present trimeric mRBD construct consists of an N-terminal trimerization domain of human cartilage matrix protein (hCMP) (hCMP residues 298-340) (accession number AAA63904) linked by a 14-residue flexible linker (ASSEGTMMRGELKN) derived from the V1 loop of

HIV-1 JR-FL gp120 linked to RBD residues 332-532 (accession number YP_009724390.1) with an engineered glycosylation site (NGS) at N532 fused to an HRV-3C precision protease cleavage site linked to a 10x Histidine tag by a GS linker. The hCMP-mRBD construct reincorporated a glycosylation motif "NIT" at the N-terminal of the mRBD recapitulating the native glycosylation site at N331 in SARS-CoV-2 RBD.

The C-terminal fusion of hCMP trimerization domain was obtained by fusing mRBD (residues 332-532) to hCMP (residues 298-340) by a five-residue linker (GSAGS). This construct is termed mRBD-hCMP. Additionally, the C-terminal fusion of Glycosylated IZ trimerization domain was obtained by fusing mRBD (residues 332-532) to Glycosylated IZ (residues "NGTGRMKQIEDKIENITSKIYNITNEIARIKKLIGNRTAS") by a five residue linker (GSAGS). This construct is termed mRBD-GlyIZ.

mRBD (residues 332-532) was fused to SpyCatcher (residues 440-549) and the construct was termed mRBD-SpyCatcher.

These constructs were fused to a precision protease (HRV-3C) cleavage site linked to a 10x Histidine tag by a GS linker. These constructs were cloned into the mammalian expression vector pcDNA3.4 under control of a CMV promoter and efficient protein secretion was enabled by the tPA secretion signal peptide sequence. CR3022 antibody heavy and light chain genes were synthesised and subcloned into pcDNA3.4 vector by Genscript (USA).

Purification of recombinant proteins expressed in *Expi293F* cells

mRBD, hCMP-mRBD, mRBD-hCMP, mRBD-GlyIZ, mRBD-SpyCatcher, mSpyCatcher protein was purified from transiently transfected Expi293F cells following manufacturer's guidelines (Gibco, Thermofisher) as described previously [37]. A minimum of three independent batches of purifications were performed for all the constructs.

Tag removal

HRV-3C precision protease digestion was performed to remove the C-terminal 10xHis tag (Protein: HRV-3C = 50:1). HRV-3C digestion was performed for 16 hrs at 4 °C in PBS (pH 7·4). Ni Sepharose 6 Fast flow resin (GE Healthcare) affinity exclusion chromatography was performed to obtain the tagless protein (containing the tag C-terminal sequence: LEVLFQ). The unbound tagless proteins concentration was determined by absorbance (A_{280}) using NanoDrop™2000c with the theoretical molar extinction coefficient calculated using the ProtParam tool (ExPASy).

MsDPS2-SpyTag nanoparticle, mRBD-SpyCatcher construct purification and complexation

Protein nanoparticles present an attractive platform for antigenic display and immune stimulation by mimicking natural infection [79]. In this study, we conjugated mammalian purified RBD (mRBD) from SAR-CoV-2 virus to a self-assembling bacterial protein - DNA Binding Protein from Starved cells, isolated from *Mycobacterium smegmatis* (MsDPS2) (PDB ID: 2Z90). MsDPS2 is purified from *E. coli* as a dodecameric protein making it an excellent choice of vaccine nanoplatform [46]. To enable flexible conjugation, we utilized the SpyTag/SpyCatcher protein coupling strategy, created by splitting the CnaB2 domain of S*treptococcus pyogenes* protein FbaB [45]. We designed an Msdps2-SpyTag construct by genetic fusion of the 13 residue SpyTag at the C-terminus of a single subunit of the MsDPS2 through a 15 residue linker. MsDPS2-SpyTag protein was expressed in *E. coli* BL21 cells by an overnight induction with IPTG at 20 ºC and purified from the cell supernatant as a soluble dodecameric protein using a Ni-NTA column. Similarly, an mRBD_SpyCatcher construct was made by genetically fusing

the SpyCatcher at the C-terminal of the mammalian expressed RBD. mRBD_SpyCatcher, which is a monomeric protein, was purified by Ni-NTA chromatography from culture supernatant of transiently transfected *Expi293F*. Purified mRBD2-SpyCatcher is monomeric as confirmed by SDS-PAGE. MsDPS2-Spytag and mRBD2-SpyCatcher, were mixed in 1:3 molar ratio and the reaction was incubated at 25 °C for 3 hours. Conjugation reaction was checked on 12 % SDS PAGE. The protein complex conjugated with mRBD2-SpyCatcher was purified using Superose-6 10/300 analytical column. SDS-PAGE and SEC confirmed the complexation of MsDPS2-SpyTag with mRBD-SpyCatcher.

SDS-PAGE analysis, Size exclusion chromatography (SEC) and SEC-MALS

Protein purity was estimated by denaturing PAGE. Samples were denatured in SDS containing sample buffer by boiling in reducing (with β-mercaptoethanol) or non-reducing (without β-mercaptoethanol) conditions.

SEC profiles were obtained in 1xPBS buffer equilibrated analytical gel filtration Superdex-200 10/300GL column (GE healthcare) on an Äkta pure chromatography system. The peak area under the curve (AUC) was determined in the Evaluation platform using the peak integrate tool. For SEC-MALS (multi angle light scattering), a PBS (pH 7.4) buffer equilibrated analytical Superdex-200 10/300GL gel filtration column (GE healthcare) on a SHIMADZU HPLC was utilized to resolve hCMP-mRBD purified protein. Gel filtration resolved protein peaks were subjected to in-line refractive index (WATERS corp.) and MALS (mini DAWN TREOS, Wyatt Technology corp.) detection for molar mass determination. The acquired data from UV, MALS and RI were analysed using ASTRA™ software (Wyatt Technology).

nanoDSF thermal melt studies

Equilibrium thermal unfolding of hCMP-mRBD (- 10xHis tag) protein, before or after thermal stress was carried out using a nanoDSF (Prometheus NT.48) as described previously [37]. Two independent measurements were carried out in duplicate with 2-4 µM of protein in the temperature range of 15-95 °C at 100% LED power and initial discovery scan counts (350nm) ranging between 5000 and 10000. In all cases, when lyophilized protein was used, it was reconstituted in water, prior to DSF.

SPR-binding of hCMP-mRBD analyte to immobilized ACE2-hFc/CR3022

hCMP-mRBD protein kinetic binding studies to ACE2-hFc and CR3022 antibody were performed on a ProteOn XPR36 Protein Interaction Array V.3.1 (Bio-Rad). The GLM sensor chip was activated with sulfo-NHS and EDC (Sigma) reaction. Protein G (Sigma) was covalently coupled following activation. ~3500-4000 RU of Protein G (10 µg/mL) was coupled in 10mM sodium acetate buffer pH 4·5 at a flow rate of 30 µl/min for 300 seconds in desired channels. Finally, 1M ethanolamine was used to quench the excess sulfo-NHS esters. Following quenching, ligand immobilization was carried out at a flow rate of 30 µl/min for 100 seconds. ACE2-hFc or CR3022 were immobilized at ~800 RU on desired channels excluding a single blank channel that acts as the reference channel. hCMP-mRBD analyte interaction with ligands was monitored by passing over the chip at a flow rate of 30 µl/min for 200 seconds, and the subsequent dissociation phase was monitored for 600 seconds. An empty lane without ligand immobilization was utilized for measuring non-specific binding. Following each kinetic assay, regeneration was carried out with 0.1 M Glycine-HCl (pH 2.7). The ligand immobilization cycle was repeated prior to each kinetic assay. Various concentrations of the hCMP-mRBD (- 10xHis tag) (100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM) in 1x PBST were

used for binding studies. The kinetic parameters were obtained by fitting the data to a simple 1:1 Langmuir interaction model using Proteon Manager.

SPR-binding of thermal stress subjected hCMP-mRBD analyte to immobilized ACE2-hFc

Lyophilized protein or protein in 1X PBS (0.2 mg/mL) was subjected to transient thermal incubation at the desired temperature in a thermal cycler for ninety or sixty minutes, respectively. Post thermal incubation, binding response was assessed at 100nM analyte concentration by SPR as mentioned in the previous section.

Mice and Guinea Pig Immunizations

Immunizations of BALBc mice (n=5/group, female, 3-4 weeks old, ~16-18 g) and Hartley strain guinea pigs (n=5/group, female, 6-8 weeks old, ~300 g) were performed with freshly adjuvanted (Sepivac SWE™ (Cat.No. 80748J, Batch no. 200915012131, SEPPIC SA, France) and/or (AddaVax™ (vac-adx-10, InvivoGen, USA))) protein (1:1 v/v Antigen : Adjuvant ratio per animal/dose, 20 µg protein in 50 µl PBS (pH 7·4) and 50 µl Adjuvant). Animals were immunized via the intramuscular route with two doses constituting prime and boost on Day 0 and 21 respectively. Sera were isolated from bleeds drawn prior to prime (day -2), post prime (day 14) and post boost (day 35). All animal studies were approved by the Institutional Animal Ethics committee (IAEC) (RR/IAEC/61-2019, Invivo/GP/084, CAF/ETHICS/798/2020, CAF/ETHICS/799/2020, CAF/ETHICS/799/2020, CAF/ETHICS/799/2020). The animal experiments were conducted in compliance to the ARRIVE guidelines [80]. Mice and guinea pig immunizations were non blinded.

Hamster experiments-

Ethics and animals' husbandry- The animal experimental work plans were reviewed and approved by the Indian Institute of Science, Institute Animals Ethical Committee (IAEC). The experiment was performed according to CPCSEA (The Committee for the Purpose of Control and Supervision of Experiments on Animals) and ARRIVE guidelines [80]. The required number (n = 4/group) of Syrian golden hamsters (*Mesorectums auratus*) of both sexes (50-60 gm of weight) were procured from the Biogen Laboratory Animal Facility (Bangalore, India). The hamsters were housed and maintained at the Central Animal Facility at IISC, Bangalore, with feed and water ad libitum. and 12hr light and dark cycle.

Hamster Immunization protocol – After two-week acclimatization of animals, hamsters (n = 4/group) were randomly grouped, and the immunization protocol initiated with the pre-bleed of animals. Hamsters were immunized with 20 ug of subunit vaccine candidate in 50ul injection volume intramuscularly, with the primary on day 0 and boosts on day 21 and 42. Bleeds were performed two weeks after each immunization. The hamster immunization study was non blinded.

Virus Challenge – After completing the immunization schedule, the hamsters were transferred to the virus BSL-3 laboratory at the Centre for Infectious Disease Research, Indian Institute of Science-Bangalore (India) and were kept in individually ventilated cages (IVC), maintained at 23 ± 1 °C and 50 ± 5 % temperature and relative humidity, respectively. After acclimatization of seven days in IVC cages at the virus BSL-3 laboratory, the hamsters were challenged with 10^6 PFU of SARS-Cov-2 US strain (USA-WA1/2020 obtained from BEI resources) intranasally in 100 µl of DMEM, by sedating/anaesthetizing the hamsters with a xylazine (10mg/kg/body wt.) and ketamine (150g/kg/body wt.) cocktail intraperitoneally. The health of hamsters, body temperatures, body weights, and clinical signs were monitored daily by an

expert veterinarian. Clinical sign scoring systems were developed similar to that described earlier with some modifications. In the present experiment considering fourteen clinical signs, we measured average clinical scores on as follows, lethargy (1 point), rough coat (1 point), Sneezing (1 point), mucus discharge from nose or eyes (1 point), Half closed eyes/ watery eyes (1 point), huddling in the corner (1 point), ear laid back (1 point), hunched back (1 point), head tilt (1 point) , moderate dyspnoea (2 points), body weight loss: 2-5% (1 point), 5-10% (2-point), 10-20% (3 point), Shaking or shivering (1 point).

On the fourth day, post challenge, all the hamsters were humanely euthanized by an overdose of xylazine through intraperitoneal injection. The left lobe of the lung was harvested and fixed in 4% paraformaldehyde (PFA) for histopathological examination of lungs. The right lobes were frozen at -80ºC for determining the virus copy number by qRT-PCR.

Histopathological Examination

Left lobes of lung, fixed in 4% of paraformaldehyde were processed, embedded in paraffin, and cut into 4 μm correct symbol, and sectioned by microtome for haematoxylin and eosin staining. The lung sections were microscopically examined and evaluated for different pathological scores by a veterinary immunologist. Four different histopathological scores were assigned as follows 1. Percent of infected part of lung tissues considering the consolidation of lung; 2. Lung inflammation scores, considering the severity of alveolar and bronchial inflammation; 3. Immune cell influx score, considering the infiltration of lung tissue with the numbers of neutrophils, macrophages and lymphocytes; 4. Edema score, considering the alveolar and perivascular edema. The scores and parameters were graded as absent (0), minimal (1), mild (2), moderate (3), or severe (4) [81].

RNA Extractions and q-RT-PCR to quantitate sub genomic viral RNA in lungs.

Three-time freeze-thawed right lower lobe from the lung of each hamster was homogenized in 1ml of RNAiso Plus Reagent (Takara) and total RNA was isolated as per the manufacturer's protocol using chloroform and isopropanol reagents. The quantity and quality (260/280 ratios) of RNA extracted was measured by Nanodrop. The extracted RNA was further diluted to 27 ng/µl in nuclease free water. The viral sub genomic RNA copy number was quantified by using 100ng of RNA/well for 10 µl of reaction mixture using AgPath-ID™ One-Step RT-PCR kit (AM1005, Applied Biosystems). The following primers and probes were used 2019-nCoV_N1-Fwd- 5'GACCCCAAAATCAGCGAAAT3'; 2019-nCoV_N1-Rev-5'TCTGGTTACTGCCAGTTGAATCTG3'; 2019-nCoV_N1 Probe (6-FAM / BHQ-1) ACCCCGCATTACGTTTGGTGGACC (Sigma Aldrich) for amplifying RNA from the SARS CoV-2 N-1 gene. The sub genomic virus copy number per 100ng of RNA was estimated by generating a standard curve from a known number of pfu of the virus.

ELISA- serum binding antibody end point titers

Desired antigens were coated (4 µg/mL, 50 µL/well, 1xPBS) on 96 well plates for two hours and incubated on a MixMate thermomixer (Eppendorf, USA) at 25 °C under constant shaking (300 rpm). Antigen immobilization was assessed by coating ACE2-hFc protein. Coated wells were washed with PBST (200µl/well) four times, and blocked using blocking solution (100 µL, 3% skimmed milk in 1xPBST) and then incubated at 25 °C for one hour, 300 rpm. Post blocking, antisera were diluted four-folds serially, starting 1:100 and incubated at 25 °C for 1 hour, 300 rpm. Post sera binding, three washes were performed (200 µL of 1xPBST/well). Following this, anti-Guinea Pig IgG secondary antibody (ALP conjugated, Rabbit origin) (diluted 1:5000 in blocking buffer) (50 µL/well) was added and incubated at 25 °C for 1 hour, 300 rpm (Sigma-Aldrich). Post incubation, four washes were performed (200 µL of

1xPBST/well) and incubated with pNPP liquid substrate (50 µL/well) (pNPP, Sigma-Aldrich) at 37 °C for 30 minutes, 300 rpm. Finally, the chromogenic signal was measured at 405 nm. The highest serum dilution possessing signal above cut-off (0.2 O.D. at 405 nm) was considered as the endpoint titer for ELISA.

Convalescent patient sera samples

Convalescent patient sera were drawn (n = 40) and assayed for pseudoviral neutralization as described in the following pseudovirus neutralization section. The ethics approval of human clinical samples were approved by Institute Human Ethical Committee (Approval No: **CSIR-IGIB/IHEC/2020-21/01**). Patients informed consent was obtained for obtaining the sera following The Code of the Ethics of the World Medical Association (Declaration of Helsinki).

Production of Pseudotyped SARS-CoV-2 and pseudovirus neutralization assay

Pseudo viral neutralization assays were performed with SARS-CoV-2 pseudo virus harbouring reporter NanoLuc luciferase gene. Briefly, HEK293T cells were transiently transfected with plasmid DNA pHIV-1 NL4·3Δenv-Luc and Spike-Δ19-D614G by using Profection mammalian transfection kit (Promega Inc) following the instructions in the kit manual. Post 48 hours, the pseudovirus containing culture supernatant was centrifuged for 10 mins at 600 xg followed by filtration via 0.22 µm filters, and stored at -80 °C until further use. 293T-hACE-2 (BEI resources, NIH, Catalog No. NR-52511) or Vero/TMPRSS2 (JCRB cell bank, JCRB #1818) cells expressing the ACE2 or ACE and TMPRSS2 receptors respectively were cultured in DMEM (Gibco) supplemented with 5 % FBS (Fetal Bovine Serum), penicillin-streptomycin (100 U/mL). Patient derived convalescent sera (n = 40) were tested for neutralization in both 293T-ACE-2 and Vero/TMPRSS2 cells whereas animal sera were tested only in

Vero/TMPRSS2 cells. Neutralization assays were done in two replicates by using heat-inactivated animal serum or human COVID-19 convalescent serum (HCS). The pseudovirus (PV) was incubated with serially diluted sera in a total volume of 100 μL for 1 hour at 37 °C. The cells (Vero/TMPRSS2 or 293T-hACE2) were then trypsinised and $1x10^4$ cells/well were added to make up the final volume of 200uL/well. The plates were further incubated for 48 hours in humidified incubator at 37 °C with 5% CO_2. After 48 hours of incubation, 140 μL supernatant was removed and 50 μL Bright-Glo luciferase substrate (Promega Inc.) was added. After 2-3 minute incubation, 80 μL lysate was transferred to white plates and luminescence was measured by using Cytation-5 multi-mode reader (BioTech Inc.) The luciferase activity measured as Relative luminescence units (RLU) from SARS-CoV-2 pseudovirus in the absence of sera was used as reference for normalizing the RLUs of wells containing sera. Pseudovirus neutralization titers (ID_{50}) were determined as the serum dilution at which infectivity was blocked by 50%. The three RBD mutations (K417N, E484K, N501Y) were introduced into the parental Spike-Δ19-D614G clone using overlap PCR and Gibson recombination. The assembled full-length Spike containing the B.1.351 RBD mutations was cloned in pcDNA3.4 vector and was confirmed by sequencing and used to generate the corresponding pseudovirus as described above. The investigators performing the neutralization assays were blinded to the group identities.

Statistical Analysis

The P values for ELISA binding titers, neutralization titers, were analysed with a two-tailed Mann-Whitney test using the GraphPad Prism software. The P values for pairwise Wt and SA pseudovirus neutralization titers were analysed utilizing the Wilcoxon Rank-Sum test. The P value for hamster weight change between virus control and unchallenged groups was analysed by two-tailed student-t test. The correlation coefficients for pseudovirus neutralization 293T-

ACE2/VeroE6-TMPRSS2 cell line pseudovirus neutralizations were analysed by Spearman correlation using the GraphPad Prism 8 software (GraphPad v8.4.3).

Ancillary Information

Supporting information

Additional experimental information methods and figures available as single pdf file.

Corresponding Author Information

Rajesh Ringe (rajeshringe@imtech.res.in), Raghavan Varadarajan (varadar@iisc.ac.in).

Author Contributions

R.V., S.K.M., conceptualized the work, designed the studies. S.P., R.V., R.S.R., planned the animal studies. R.S., constructed the stable cell lines. R.S., U.R.P., P.R., A.U., N.A., K.K., performed ELISA. S.T. standardized growth and quantitation of replicative virus. R.S.R performed the hamster immunizations and challenge studies. K.K. purified ACE2-hFc. S.K., U.R.P. performed the MsDPS2-mRBD construction characterizations. S.P., N.G., A.U., performed hCMP-mRBD protein expression and characterization. S.K.M. carried out DSF and SPR characterization. S.G. cloned the mRBD-hCMP and mRBD-GlyIZ and performed hCMP-pRBD protein expression and characterization. S.K., M.S.K., S.K.M., performed SEC-MALS. P.K., cloned the hCMP-mRBD gene. D.C. cloned the Spike with South African RBD mutations. M.B. performed the animal immunizations. I.P., S.D. provided the EM data and analysis. S.M., S.B., provided CPE neutralizing antibody assay data. R.P.R., S.Ku. designed, optimized, executed the pseudoviral neutralization assays, and analyzed the data. S.S, A.T.,

S.J., R.P. provided convalescent human serum samples. S.K.M, R.V wrote the manuscript with contributions from each author.

Data Availability

All the data are in the manuscript. Additional requests for data will be approved upon reasonable request and upon an approval of signed data access agreement.

Declaration of Interests

A provisional patent application has been filed for the RBD formulations described in this manuscript. R.V, S.K.M, S.P, R.S are inventors. R.V is a co-founder of Mynvax and S.P, R.S, U.R.P, N.A., P.R., M.B., N.G, and A.U are employees of Mynvax Private Limited.

Acknowledgements

Abbreviations

ACE2: angiotensin-converting enzyme 2; COVID-19: Coronavirus disease 2019; GlyIZ: glycosylated IZ trimerization domain; hCMP: human cartilage matrix protein trimerization domain; HCS: human convalescent sera; Msdps2: *Mycobacterium smegmatis* second DNA binding protein; NTD: N-terminal domain; RBD: Receptor Binding Domain; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SD1: short domain 1; SD-2: short domain 2; SEC-MALS: Size Exclusion Chromatography Multi Angle Light Scattering; SPR: Surface Plasmon Resonance; SWE: squalene-in-water emulsion; Wk: Week.

References

(1)   Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: A Study of a Family Cluster. *Lancet (London, England)* **2020**, *395* (10223), 514–523. https://doi.org/10.1016/S0140-6736(20)30154-9.

(2)   Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G. F.; Tan, W.; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382* (8), 727–733. https://doi.org/10.1056/NEJMoa2001017.

(3)   WHO. Coronavirus Disease (COVID-19) Dashboard https://covid19.who.int/.

(4)   Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. *Science* **2020**, *367* (6483), 1260–1263. https://doi.org/10.1126/science.abb2507.

(5)   Walls, A. C.; Park, Y.-J.; Tortorici, M. A.; Wall, A.; McGuire, A. T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**, *181* (2), 281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058.

(6)   Zost, S. J.; Gilchuk, P.; Case, J. B.; Binshtein, E.; Chen, R. E.; Nkolola, J. P.; Schäfer, A.; Reidy, J. X.; Trivette, A.; Nargi, R. S.; Sutton, R. E.; Suryadevara, N.; Martinez, D. R.; Williamson, L. E.; Chen, E. C.; Jones, T.; Day, S.; Myers, L.; Hassan, A. O.; Kafai, N. M.; Winkler, E. S.; Fox, J. M.; Shrihari, S.; Mueller, B. K.; Meiler, J.; Chandrashekar, A.; Mercado, N. B.; Steinhardt, J. J.; Ren, K.; Loo, Y.-M.; Kallewaard, N. L.; McCune, B. T.; Keeler, S. P.; Holtzman, M. J.; Barouch, D. H.; Gralinski, L. E.; Baric, R. S.; Thackray, L. B.; Diamond, M. S.; Carnahan, R. H.; Crowe, J. E. Potently Neutralizing and Protective Human Antibodies against SARS-CoV-2. *Nature* **2020**, *584* (7821), 443–449. https://doi.org/10.1038/s41586-020-2548-6.

(7)   Zost, S. J.; Gilchuk, P.; Chen, R. E.; Case, J. B.; Reidy, J. X.; Trivette, A.; Nargi, R. S.; Sutton, R. E.; Suryadevara, N.; Chen, E. C.; Binshtein, E.; Shrihari, S.; Ostrowski, M.; Chu, H. Y.; Didier, J. E.; MacRenaris, K. W.; Jones, T.; Day, S.; Myers, L.; Eun-Hyung Lee, F.; Nguyen, D. C.; Sanz, I.; Martinez, D. R.; Rothlauf, P. W.; Bloyet, L.-M.; Whelan, S. P. J.; Baric, R. S.; Thackray, L. B.; Diamond, M. S.; Carnahan, R. H.; Crowe, J. E. Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein. *Nat. Med.* **2020**, *26* (9), 1422–1427. https://doi.org/10.1038/s41591-020-0998-x.

(8)   Barnes, C. O.; Jette, C. A.; Abernathy, M. E.; Dam, K.-M. A.; Esswein, S. R.; Gristick, H. B.; Malyutin, A. G.; Sharaf, N. G.; Huey-Tubman, K. E.; Lee, Y. E.; Robbiani, D. F.; Nussenzweig, M. C.; West, A. P.; Bjorkman, P. J. SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic Strategies. *Nature* **2020**, *588* (7839), 682–687. https://doi.org/10.1038/s41586-020-2852-1.

(9)   Barnes, C. O.; West, A. P.; Huey-Tubman, K. E.; Hoffmann, M. A. G.; Sharaf, N. G.; Hoffman, P. R.; Koranda, N.; Gristick, H. B.; Gaebler, C.; Muecksch, F.; Lorenzi, J. C.

C.; Finkin, S.; Hägglöf, T.; Hurley, A.; Millard, K. G.; Weisblum, Y.; Schmidt, F.; Hatziioannou, T.; Bieniasz, P. D.; Caskey, M.; Robbiani, D. F.; Nussenzweig, M. C.; Bjorkman, P. J. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **2020**, *182* (4), 828-842.e16. https://doi.org/10.1016/j.cell.2020.06.025.

(10) Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; Chen, Z.; Guo, Y.; Zhang, J.; Li, Y.; Song, X.; Chen, Y.; Xia, L.; Fu, L.; Hou, L.; Xu, J.; Yu, C.; Li, J.; Zhou, Q.; Chen, W. A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2. *Science* **2020**, *369* (6504), 650–655. https://doi.org/10.1126/science.abc6952.

(11) Robbiani, D. F.; Gaebler, C.; Muecksch, F.; Lorenzi, J. C. C.; Wang, Z.; Cho, A.; Agudelo, M.; Barnes, C. O.; Gazumyan, A.; Finkin, S.; Hägglöf, T.; Oliveira, T. Y.; Viant, C.; Hurley, A.; Hoffmann, H.-H.; Millard, K. G.; Kost, R. G.; Cipolla, M.; Gordon, K.; Bianchini, F.; Chen, S. T.; Ramos, V.; Patel, R.; Dizon, J.; Shimeliovich, I.; Mendoza, P.; Hartweger, H.; Nogueira, L.; Pack, M.; Horowitz, J.; Schmidt, F.; Weisblum, Y.; Michailidis, E.; Ashbrook, A. W.; Waltari, E.; Pak, J. E.; Huey-Tubman, K. E.; Koranda, N.; Hoffman, P. R.; West, A. P.; Rice, C. M.; Hatziioannou, T.; Bjorkman, P. J.; Bieniasz, P. D.; Caskey, M.; Nussenzweig, M. C. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals. *Nature* **2020**, *584* (7821), 437–442. https://doi.org/10.1038/s41586-020-2456-9.

(12) Wu, Y.; Wang, F.; Shen, C.; Peng, W.; Li, D.; Zhao, C.; Li, Z.; Li, S.; Bi, Y.; Yang, Y.; Gong, Y.; Xiao, H.; Fan, Z.; Tan, S.; Wu, G.; Tan, W.; Lu, X.; Fan, C.; Wang, Q.; Liu, Y.; Zhang, C.; Qi, J.; Gao, G. F.; Gao, F.; Liu, L. A Noncompeting Pair of Human Neutralizing Antibodies Block COVID-19 Virus Binding to Its Receptor ACE2. *Science* **2020**, *368* (6496), 1274–1278. https://doi.org/10.1126/science.abc2241.

(13) Cao, Y.; Su, B.; Guo, X.; Sun, W.; Deng, Y.; Bao, L.; Zhu, Q.; Zhang, X.; Zheng, Y.; Geng, C.; Chai, X.; He, R.; Li, X.; Lv, Q.; Zhu, H.; Deng, W.; Xu, Y.; Wang, Y.; Qiao, L.; Tan, Y.; Song, L.; Wang, G.; Du, X.; Gao, N.; Liu, J.; Xiao, J.; Su, X.; Du, Z.; Feng, Y.; Qin, C.; Qin, C.; Jin, R.; Xie, X. S. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **2020**, *182* (1), 73-84.e16. https://doi.org/10.1016/j.cell.2020.05.025.

(14) Kreer, C.; Zehner, M.; Weber, T.; Ercanoglu, M. S.; Gieselmann, L.; Rohde, C.; Halwe, S.; Korenkov, M.; Schommers, P.; Vanshylla, K.; Di Cristanziano, V.; Janicki, H.; Brinker, R.; Ashurov, A.; Krähling, V.; Kupke, A.; Cohen-Dvashi, H.; Koch, M.; Eckert, J. M.; Lederer, S.; Pfeifer, N.; Wolf, T.; Vehreschild, M. J. G. T.; Wendtner, C.; Diskin, R.; Gruell, H.; Becker, S.; Klein, F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. *Cell* **2020**, *182* (4), 843-854.e12. https://doi.org/10.1016/j.cell.2020.06.044.

(15) Liu, L.; Wang, P.; Nair, M. S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J. F. W.; Sahi, V.; Figueroa, A.; Guo, X. V.; Cerutti, G.; Bimela, J.; Gorman, J.; Zhou, T.; Chen, Z.; Yuen, K.-Y.; Kwong, P. D.; Sodroski, J. G.; Yin, M. T.; Sheng, Z.; Huang, Y.; Shapiro, L.; Ho, D. D. Potent Neutralizing Antibodies against Multiple Epitopes on SARS-CoV-2 Spike. *Nature* **2020**, *584* (7821), 450–456. https://doi.org/10.1038/s41586-020-2571-7.

(16) Kemp, S. A.; Harvey, W. T.; Datir, R. P.; Collier, D. A.; Ferreira, I.; Carabelli, A. M.;

Robertson, D. L.; Gupta, R. K. Recurrent Emergence and Transmission of a SARS-CoV-2 Spike Deletion ΔH69/V70. *bioRxiv* **2020**, 2020.12.14.422555. https://doi.org/10.1101/2020.12.14.422555.

(17)   Korber, B.; Fischer, W. M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E. E.; Bhattacharya, T.; Foley, B.; Hastie, K. M.; Parker, M. D.; Partridge, D. G.; Evans, C. M.; Freeman, T. M.; de Silva, T. I.; McDanal, C.; Perez, L. G.; Tang, H.; Moon-Walker, A.; Whelan, S. P.; LaBranche, C. C.; Saphire, E. O.; Montefiori, D. C.; Angyal, A.; Brown, R. L.; Carrilero, L.; Green, L. R.; Groves, D. C.; Johnson, K. J.; Keeley, A. J.; Lindsey, B. B.; Parsons, P. J.; Raza, M.; Rowland-Jones, S.; Smith, N.; Tucker, R. M.; Wang, D.; Wyles, M. D. Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. *Cell* **2020**, *182* (4), 812-827.e19. https://doi.org/10.1016/j.cell.2020.06.043.

(18)   Andreano, E.; Piccini, G.; Licastro, D.; Casalino, L.; Johnson, N. V; Paciello, I.; Monego, S. D.; Pantano, E.; Manganaro, N.; Manenti, A.; Manna, R.; Casa, E.; Hyseni, I.; Benincasa, L.; Montomoli, E.; Amaro, R. E.; McLellan, J. S.; Rappuoli, R. SARS-CoV-2 Escape <Em>in Vitro</Em> from a Highly Neutralizing COVID-19 Convalescent Plasma. *bioRxiv* **2020**, 2020.12.28.424451. https://doi.org/10.1101/2020.12.28.424451.

(19)   Greaney, A. J.; Loes, A. N.; Crawford, K. H. D.; Starr, T. N.; Malone, K. D.; Chu, H. Y.; Bloom, J. D. Comprehensive Mapping of Mutations to the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition by Polyclonal Human Serum Antibodies. *bioRxiv* **2021**, 2020.12.31.425021. https://doi.org/10.1101/2020.12.31.425021.

(20)   Kim, Y.-I.; Kim, S.-M.; Park, S.-J.; Kim, E.-H.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Casel, M. A. B.; Rollon, R.; Jang, S.-G.; Um, J.; Song, M.-S.; Jeong, H. W.; Kim, E.-G.; Kim, Y.; Kim, S. Y.; Park, J.-S.; Park, M. S.; Kwon, G.-Y.; Yeo, S. G.; Lee, S.-A.; Choi, Y. J.; Jung, J. U.; Choi, Y. K. Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission. *Emerg. Microbes Infect.* **2021**, 1–28. https://doi.org/10.1080/22221751.2021.1872352.

(21)   Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell Entry Mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci.* **2020**, *117* (21), 11727–11734. https://doi.org/10.1073/pnas.2003138117.

(22)   Bosch, B. J.; van der Zee, R.; de Haan, C. A. M.; Rottier, P. J. M. The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. *J. Virol.* **2003**, *77* (16), 8801–8811. https://doi.org/10.1128/jvi.77.16.8801-8811.2003.

(23)   Brouwer, P. J. M.; Caniels, T. G.; van der Straten, K.; Snitselaar, J. L.; Aldon, Y.; Bangaru, S.; Torres, J. L.; Okba, N. M. A.; Claireaux, M.; Kerster, G.; Bentlage, A. E. H.; van Haaren, M. M.; Guerra, D.; Burger, J. A.; Schermer, E. E.; Verheul, K. D.; van der Velde, N.; van der Kooi, A.; van Schooten, J.; van Breemen, M. J.; Bijl, T. P. L.; Sliepen, K.; Aartse, A.; Derking, R.; Bontjer, I.; Kootstra, N. A.; Wiersinga, W. J.; Vidarsson, G.; Haagmans, B. L.; Ward, A. B.; de Bree, G. J.; Sanders, R. W.; van Gils, M. J. Potent Neutralizing Antibodies from COVID-19 Patients Define Multiple Targets of Vulnerability. *Science* **2020**, *369* (6504), 643–650. https://doi.org/10.1126/science.abc5902.

(24)   Huo, J.; Zhao, Y.; Ren, J.; Zhou, D.; Duyvesteyn, H. M. E.; Ginn, H. M.; Carrique, L.;

Malinauskas, T.; Ruza, R. R.; Shah, P. N. M.; Tan, T. K.; Rijal, P.; Coombes, N.; Bewley, K. R.; Tree, J. A.; Radecke, J.; Paterson, N. G.; Supasa, P.; Mongkolsapaya, J.; Screaton, G. R.; Carroll, M.; Townsend, A.; Fry, E. E.; Owens, R. J.; Stuart, D. I. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host Microbe* **2020**, *28* (3), 445-454.e6. https://doi.org/10.1016/j.chom.2020.06.010.

(25) Pinto, D.; Park, Y.-J.; Beltramello, M.; Walls, A. C.; Tortorici, M. A.; Bianchi, S.; Jaconi, S.; Culap, K.; Zatta, F.; De Marco, A.; Peter, A.; Guarino, B.; Spreafico, R.; Cameroni, E.; Case, J. B.; Chen, R. E.; Havenar-Daughton, C.; Snell, G.; Telenti, A.; Virgin, H. W.; Lanzavecchia, A.; Diamond, M. S.; Fink, K.; Veesler, D.; Corti, D. Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. *Nature* **2020**, *583* (7815), 290–295. https://doi.org/10.1038/s41586-020-2349-y.

(26) Rogers, T. F.; Zhao, F.; Huang, D.; Beutler, N.; Burns, A.; He, W.-T.; Limbo, O.; Smith, C.; Song, G.; Woehl, J.; Yang, L.; Abbott, R. K.; Callaghan, S.; Garcia, E.; Hurtado, J.; Parren, M.; Peng, L.; Ramirez, S.; Ricketts, J.; Ricciardi, M. J.; Rawlings, S. A.; Wu, N. C.; Yuan, M.; Smith, D. M.; Nemazee, D.; Teijaro, J. R.; Voss, J. E.; Wilson, I. A.; Andrabi, R.; Briney, B.; Landais, E.; Sok, D.; Jardine, J. G.; Burton, D. R. Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model. *Science* **2020**, *369* (6506), 956–963. https://doi.org/10.1126/science.abc7520.

(27) Shi, R.; Shan, C.; Duan, X.; Chen, Z.; Liu, P.; Song, J.; Song, T.; Bi, X.; Han, C.; Wu, L.; Gao, G.; Hu, X.; Zhang, Y.; Tong, Z.; Huang, W.; Liu, W. J.; Wu, G.; Zhang, B.; Wang, L.; Qi, J.; Feng, H.; Wang, F.-S.; Wang, Q.; Gao, G. F.; Yuan, Z.; Yan, J. A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-CoV-2. *Nature* **2020**, *584* (7819), 120–124. https://doi.org/10.1038/s41586-020-2381-y.

(28) Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.-Y.; Wang, Q.; Zhou, H.; Yan, J.; Qi, J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **2020**, *181* (4), 894-904.e9. https://doi.org/10.1016/j.cell.2020.03.045.

(29) Chen, W.-H.; Tao, X.; Peng, B.-H.; Pollet, J.; Strych, U.; Bottazzi, M. E.; Hotez, P. J.; Lustigman, S.; Du, L.; Jiang, S.; Tseng, C.-T. K. Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement. *bioRxiv* **2020**, 2020.05.15.098079. https://doi.org/10.1101/2020.05.15.098079.

(30) Mulligan, M. J.; Lyke, K. E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K. A.; Li, P.; Koury, K.; Kalina, W.; Cooper, D.; Fontes-Garfias, C.; Shi, P.-Y.; Türeci, Ö.; Tompkins, K. R.; Walsh, E. E.; Frenck, R.; Falsey, A. R.; Dormitzer, P. R.; Gruber, W. C.; Şahin, U.; Jansen, K. U. Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults. *Nature* **2020**, *586* (7830), 589–593. https://doi.org/10.1038/s41586-020-2639-4.

(31) Brouwer, P. J. M.; Brinkkemper, M.; Maisonnasse, P.; Dereuddre-Bosquet, N.; Grobben, M.; Claireaux, M.; de Gast, M.; Marlin, R.; Chesnais, V.; Diry, S.; Allen, J. D.; Watanabe, Y.; Giezen, J. M.; Kerster, G.; Turner, H. L.; van der Straten, K.; van der Linden, C. A.; Aldon, Y.; Naninck, T.; Bontjer, I.; Burger, J. A.; Poniman, M.; Mykytyn, A. Z.; Okba, N. M. A.; Schermer, E. E.; van Breemen, M. J.; Ravichandran, R.; Caniels, T. G.; van Schooten, J.; Kahlaoui, N.; Contreras, V.; Lemaître, J.; Chapon, C.; Ho Tsong Fang, R.; Villaudy, J.; Sliepen, K.; van der Velden, Y. U.; Haagmans, B. L.; de Bree, G.

J.; Ginoux, E.; Ward, A. B.; Crispin, M.; King, N. P.; van der Werf, S.; van Gils, M. J.; Grand, R. Le; Sanders, R. W. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection. *bioRxiv* **2020**, 2020.11.07.365726. https://doi.org/10.1101/2020.11.07.365726.

(32) Bouwman, K. M.; Tomris, I.; Turner, H. L.; Van Der 4 Woude, R.; Bosman, G. P.; Rockx, B.; Herfst, S.; Haagmans, B. L.; Ward, A. B.; Boons, G.-J.; De Vries, R. P. Multimerization-and Glycosylation-Dependent Receptor Binding of SARS-1 CoV-2 Spike Proteins. *bioRxiv* **2020**, 2020.09.04.282558. https://doi.org/10.1101/2020.09.04.282558.

(33) Quinlan, B. D.; Mou, H.; Zhang, L.; Guo, Y.; He, W.; Ojha, A.; Parcells, M. S.; Luo, G.; Li, W.; Zhong, G.; Choe, H.; Farzan, M. The SARS-CoV-2 Receptor-Binding Domain Elicits a Potent Neutralizing Response without Antibody-Dependent Enhancement. *bioRxiv* **2020**, 2020.04.10.036418. https://doi.org/10.1101/2020.04.10.036418.

(34) Ravichandran, S.; Coyle, E. M.; Klenow, L.; Tang, J.; Grubbs, G.; Liu, S.; Wang, T.; Golding, H.; Khurana, S. Antibody Signature Induced by SARS-CoV-2 Spike Protein Immunogens in Rabbits. *Sci. Transl. Med.* **2020**, *12* (550), eabc3539. https://doi.org/10.1126/scitranslmed.abc3539.

(35) Yang, J.; Wang, W.; Chen, Z.; Lu, S.; Yang, F.; Bi, Z.; Bao, L.; Mo, F.; Li, X.; Huang, Y.; Hong, W.; Yang, Y.; Zhao, Y.; Ye, F.; Lin, S.; Deng, W.; Chen, H.; Lei, H.; Zhang, Z.; Luo, M.; Gao, H.; Zheng, Y.; Gong, Y.; Jiang, X.; Xu, Y.; Lv, Q.; Li, D.; Wang, M.; Li, F.; Wang, S.; Wang, G.; Yu, P.; Qu, Y.; Yang, L.; Deng, H.; Tong, A.; Li, J.; Wang, Z.; Yang, J.; Shen, G.; Zhao, Z.; Li, Y.; Luo, J.; Liu, H.; Yu, W.; Yang, M.; Xu, J.; Wang, J.; Li, H.; Wang, H.; Kuang, D.; Lin, P.; Hu, Z.; Guo, W.; Cheng, W.; He, Y.; Song, X.; Chen, C.; Xue, Z.; Yao, S.; Chen, L.; Ma, X.; Chen, S.; Gou, M.; Huang, W.; Wang, Y.; Fan, C.; Tian, Z.; Shi, M.; Wang, F.-S.; Dai, L.; Wu, M.; Li, G.; Wang, G.; Peng, Y.; Qian, Z.; Huang, C.; Lau, J. Y.-N.; Yang, Z.; Wei, Y.; Cen, X.; Peng, X.; Qin, C.; Zhang, K.; Lu, G.; Wei, X. A Vaccine Targeting the RBD of the S Protein of SARS-CoV-2 Induces Protective Immunity. *Nature* **2020**, *586* (7830), 572–577. https://doi.org/10.1038/s41586-020-2599-8.

(36) Zang, J.; Gu, C.; Zhou, B.; Zhang, C.; Yang, Y.; Xu, S.; Zhang, X.; Zhou, Y.; Bai, L.; Wu, Y.; Sun, Z.; Zhang, R.; Deng, Q.; Yuan, Z.; Tang, H.; Qu, D.; Lavillette, D.; Xie, Y.; Huang, Z. Immunization with the Receptor-Binding Domain of SARS-CoV-2 Elicits Antibodies Cross-Neutralizing SARS-CoV-2 and SARS-CoV without Antibody-Dependent Enhancement. *bioRxiv* **2020**, 2020.05.21.107565. https://doi.org/10.1101/2020.05.21.107565.

(37) Malladi, S. K.; Singh, R.; Pandey, S.; Gayathri, S.; Kanjo, K.; Ahmed, S.; Khan, M. S.; Kalita, P.; Girish, N.; Upadhyaya, A.; Reddy, P.; Pramanick, I.; Bhasin, M.; Mani, S.; Bhattacharyya, S.; Joseph, J.; Thankamani, K.; Raj, V. S.; Dutta, S.; Singh, R.; Nadig, G.; Varadarajan, R. Design of a Highly Thermotolerant, Immunogenic SARS-CoV-2 Spike Fragment. *J. Biol. Chem.* **2020**, jbc.RA120.016284. https://doi.org/10.1074/jbc.RA120.016284.

(38) Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L. Characterization of the Receptor-Binding Domain (RBD) of 2019 Novel Coronavirus: Implication for Development of RBD Protein as a Viral Attachment Inhibitor and Vaccine. *Cell. Mol. Immunol.* **2020**, *17* (6), 613–620. https://doi.org/10.1038/s41423-

020-0400-4.

(39) Kit Tan, T.; Rijal, P.; Rahikainen, R.; Keeble, A. H.; Hussain, S.; Harvey, R.; Hayes, J. W.; Edwards, J. C.; McLean, R. K.; Martini, V.; Pedrera, M.; Thakur, N.; Dietrich, I.; Shelton, H.; Ludi, A.; Wilsden, G.; Zagrajek, A. K.; Bialy, D.; Bhat, S.; Stevenson-, P.; Hollinghurst, P.; Tully, M.; Moffat, K.; Chiu, C.; Gray, A.; Azhar, M.; Mioulet, V.; Newman, J.; Burman, A.; Crossley, S.; Hammond, J. A.; Tchilian, E.; Bailey, D.; Tuthill, T. J.; Graham, S. P.; Huo, J.; Tree, J. A.; Buttigieg, K. R.; Caroll, M. W.; Daniels, R. S.; McCauley, J. W.; Howarth, M.; Townsend, A. R.; Radcliffe Hospital, J. A COVID-19 Vaccine Candidate Using SpyCatcher Multimerization of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Induces Potent Neutralising Antibody Responses. *bioRxiv* **2020**, 2020.08.31.275701. https://doi.org/10.1101/2020.08.31.275701.

(40) Walls, A. C.; Fiala, B.; Schäfer, A.; Wrenn, S.; Pham, M. N.; Murphy, M.; Tse, L. V.; Shehata, L.; O'Connor, M. A.; Chen, C.; Navarro, M. J.; Miranda, M. C.; Pettie, D.; Ravichandran, R.; Kraft, J. C.; Ogohara, C.; Palser, A.; Chalk, S.; Lee, E.-C.; Guerriero, K.; Kepl, E.; Chow, C. M.; Sydeman, C.; Hodge, E. A.; Brown, B.; Fuller, J. T.; Dinnon, K. H.; Gralinski, L. E.; Leist, S. R.; Gully, K. L.; Lewis, T. B.; Guttman, M.; Chu, H. Y.; Lee, K. K.; Fuller, D. H.; Baric, R. S.; Kellam, P.; Carter, L.; Pepper, M.; Sheahan, T. P.; Veesler, D.; King, N. P. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell* **2020**, *183* (5), 1367-1382.e17. https://doi.org/10.1016/j.cell.2020.10.043.

(41) Dai, L.; Zheng, T.; Xu, K.; Han, Y.; Xu, L.; Huang, E.; An, Y.; Cheng, Y.; Li, S.; Liu, M.; Yang, M.; Li, Y.; Cheng, H.; Yuan, Y.; Zhang, W.; Ke, C.; Wong, G.; Qi, J.; Qin, C.; Yan, J.; Gao, G. F. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell* **2020**, *182* (3), 722-733.e11. https://doi.org/10.1016/j.cell.2020.06.035.

(42) Lainšček, D.; Fink, T.; Forstnerič, V.; Hafner-Bratkovič, I.; Orehek, S.; Strmšek, Ž.; Manček-Keber, M.; Pečan, P.; Esih, H.; Malenšek, Š.; Aupič, J.; Dekleva, P.; Plaper, T.; Vidmar, S.; Kadunc, L.; Benčina, M.; Omersa, N.; Anderluh, G.; Pojer, F.; Lau, K.; Hacker, D.; Correia, B.; Peterhoff, D.; Wagner, R.; Jerala, R. Immune Response to Vaccine Candidates Based on Different Types of Nanoscaffolded RBD Domain of the SARS-CoV-2 Spike Protein. *bioRxiv* **2020**, 2020.08.28.244269. https://doi.org/10.1101/2020.08.28.244269.

(43) Powell, A. E.; Zhang, K.; Sanyal, M.; Tang, S.; Weidenbacher, P. A.; Li, S.; Pham, T. D.; Pak, J. E.; Chiu, W.; Kim, P. S. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. *bioRxiv* **2020**, 2020.08.28.272518. https://doi.org/10.1101/2020.08.28.272518.

(44) Sliepen, K.; van Montfort, T.; Melchers, M.; Isik, G.; Sanders, R. W. Immunosilencing a Highly Immunogenic Protein Trimerization Domain. *J. Biol. Chem.* **2015**, *290* (12), 7436–7442. https://doi.org/10.1074/jbc.M114.620534.

(45) Zakeri, B.; Fierer, J. O.; Celik, E.; Chittock, E. C.; Schwarz-Linek, U.; Moy, V. T.; Howarth, M. Peptide Tag Forming a Rapid Covalent Bond to a Protein, through Engineering a Bacterial Adhesin. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109* (12), E690–E697. https://doi.org/10.1073/pnas.1115485109.

(46) Roy, S.; Saraswathi, R.; Chatterji, D.; Vijayan, M. Structural Studies on the Second Mycobacterium Smegmatis Dps: Invariant and Variable Features of Structure,

Assembly and Function. *J. Mol. Biol.* **2008**, *375* (4), 948–959. https://doi.org/10.1016/j.jmb.2007.10.023.

(47) O'Hagan, D. T.; Ott, G. S.; Nest, G. Van; Rappuoli, R.; Giudice, G. Del. The History of MF59 ® Adjuvant: A Phoenix That Arose from the Ashes. *Expert Rev. Vaccines* **2013**, *12* (1), 13–30. https://doi.org/10.1586/erv.12.140.

(48) Kesavardhana, S.; Das, R.; Citron, M.; Datta, R.; Ecto, L.; Srilatha, N. S.; DiStefano, D.; Swoyer, R.; Joyce, J. G.; Dutta, S.; LaBranche, C. C.; Montefiori, D. C.; Flynn, J. A.; Varadarajan, R. Structure-Based Design of Cyclically Permuted HIV-1 Gp120 Trimers That Elicit Neutralizing Antibodies. *J. Biol. Chem.* **2017**, *292* (1), 278–291. https://doi.org/10.1074/jbc.M116.725614.

(49) Marcandalli, J.; Fiala, B.; Ols, S.; Perotti, M.; de van der Schueren, W.; Snijder, J.; Hodge, E.; Benhaim, M.; Ravichandran, R.; Carter, L.; Sheffler, W.; Brunner, L.; Lawrenz, M.; Dubois, P.; Lanzavecchia, A.; Sallusto, F.; Lee, K. K.; Veesler, D.; Correnti, C. E.; Stewart, L. J.; Baker, D.; Loré, K.; Perez, L.; King, N. P. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. *Cell* **2019**, *176* (6), 1420-1431.e17. https://doi.org/10.1016/j.cell.2019.01.046.

(50) Brouwer, P. J. M.; Antanasijevic, A.; Berndsen, Z.; Yasmeen, A.; Fiala, B.; Bijl, T. P. L.; Bontjer, I.; Bale, J. B.; Sheffler, W.; Allen, J. D.; Schorcht, A.; Burger, J. A.; Camacho, M.; Ellis, D.; Cottrell, C. A.; Behrens, A.-J.; Catalano, M.; del Moral-Sánchez, I.; Ketas, T. J.; LaBranche, C.; van Gils, M. J.; Sliepen, K.; Stewart, L. J.; Crispin, M.; Montefiori, D. C.; Baker, D.; Moore, J. P.; Klasse, P. J.; Ward, A. B.; King, N. P.; Sanders, R. W. Enhancing and Shaping the Immunogenicity of Native-like HIV-1 Envelope Trimers with a Two-Component Protein Nanoparticle. *Nat. Commun.* **2019**, *10* (1), 4272. https://doi.org/10.1038/s41467-019-12080-1.

(51) Ueda, G.; Antanasijevic, A.; Fallas, J. A.; Sheffler, W.; Copps, J.; Ellis, D.; Hutchinson, G. B.; Moyer, A.; Yasmeen, A.; Tsybovsky, Y.; Park, Y.-J.; Bick, M. J.; Sankaran, B.; Gillespie, R. A.; Brouwer, P. J.; Zwart, P. H.; Veesler, D.; Kanekiyo, M.; Graham, B. S.; Sanders, R. W.; Moore, J. P.; Klasse, P. J.; Ward, A. B.; King, N. P.; Baker, D. Tailored Design of Protein Nanoparticle Scaffolds for Multivalent Presentation of Viral Glycoprotein Antigens. *Elife* **2020**, *9*. https://doi.org/10.7554/eLife.57659.

(52) López-Sagaseta, J.; Malito, E.; Rappuoli, R.; Bottomley, M. J. Self-Assembling Protein Nanoparticles in the Design of Vaccines. *Comput. Struct. Biotechnol. J.* **2016**, *14*, 58–68. https://doi.org/10.1016/j.csbj.2015.11.001.

(53) Kesavardhana, S.; Varadarajan, R. Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the Heterodimeric Interface of the Gp41 Postfusion Six-Helix Bundle. *J. Virol.* **2014**, *88* (17), 9590–9604. https://doi.org/10.1128/JVI.00494-14.

(54) Jones, A. T.; Chamcha, V.; Kesavardhana, S.; Shen, X.; Beaumont, D.; Das, R.; Wyatt, L. S.; LaBranche, C. C.; Stanfield-Oakley, S.; Ferrari, G.; Montefiori, D. C.; Moss, B.; Tomaras, G. D.; Varadarajan, R.; Amara, R. R. A Trimeric HIV-1 Envelope Gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. *J. Virol.* **2017**, *92* (5), e01796-17. https://doi.org/10.1128/JVI.01796-17.

(55) Jones, A. T.; Shen, X.; Walter, K. L.; LaBranche, C. C.; Wyatt, L. S.; Tomaras, G. D.; Montefiori, D. C.; Moss, B.; Barouch, D. H.; Clements, J. D.; Kozlowski, P. A.;

Varadarajan, R.; Amara, R. R. HIV-1 Vaccination by Needle-Free Oral Injection Induces Strong Mucosal Immunity and Protects against SHIV Challenge. *Nat. Commun.* **2019**, *10* (1), 798. https://doi.org/10.1038/s41467-019-08739-4.

(56) Saha, P.; Bhattacharyya, S.; Kesavardhana, S.; Miranda, E. R.; Ali, P. S. S.; Sharma, D.; Varadarajan, R. Designed Cyclic Permutants of HIV-1 Gp120: Implications for Envelope Trimer Structure and Immunogen Design. *Biochemistry* **2012**, *51* (9), 1836–1847. https://doi.org/10.1021/bi300003v.

(57) Kar, U.; Garg, P.; Khaleeq, S.; Vignesh, V. S.; Upadhyaya, A.; Das, M.; Pandey, S.; Dutta, S.; Varadarajan, R. Design of Bacterially Expressed Influenza Stem Immunogens Displayed on Msdps2 Protein Nanoparticles. *bioRxiv* **2021**, 2021.03.14.435294. https://doi.org/10.1101/2021.03.14.435294.

(58) Corbett, K. S.; Edwards, D. K.; Leist, S. R.; Abiona, O. M.; Boyoglu-Barnum, S.; Gillespie, R. A.; Himansu, S.; Schäfer, A.; Ziwawo, C. T.; DiPiazza, A. T.; Dinnon, K. H.; Elbashir, S. M.; Shaw, C. A.; Woods, A.; Fritch, E. J.; Martinez, D. R.; Bock, K. W.; Minai, M.; Nagata, B. M.; Hutchinson, G. B.; Wu, K.; Henry, C.; Bahl, K.; Garcia-Dominguez, D.; Ma, L.; Renzi, I.; Kong, W.-P.; Schmidt, S. D.; Wang, L.; Zhang, Y.; Phung, E.; Chang, L. A.; Loomis, R. J.; Altaras, N. E.; Narayanan, E.; Metkar, M.; Presnyak, V.; Liu, C.; Louder, M. K.; Shi, W.; Leung, K.; Yang, E. S.; West, A.; Gully, K. L.; Stevens, L. J.; Wang, N.; Wrapp, D.; Doria-Rose, N. A.; Stewart-Jones, G.; Bennett, H.; Alvarado, G. S.; Nason, M. C.; Ruckwardt, T. J.; McLellan, J. S.; Denison, M. R.; Chappell, J. D.; Moore, I. N.; Morabito, K. M.; Mascola, J. R.; Baric, R. S.; Carfi, A.; Graham, B. S. SARS-CoV-2 MRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. *Nature* **2020**, *586* (7830), 567–571. https://doi.org/10.1038/s41586-020-2622-0.

(59) Jackson, L. A.; Anderson, E. J.; Rouphael, N. G.; Roberts, P. C.; Makhene, M.; Coler, R. N.; McCullough, M. P.; Chappell, J. D.; Denison, M. R.; Stevens, L. J.; Pruijssers, A. J.; McDermott, A.; Flach, B.; Doria-Rose, N. A.; Corbett, K. S.; Morabito, K. M.; O'Dell, S.; Schmidt, S. D.; Swanson, P. A.; Padilla, M.; Mascola, J. R.; Neuzil, K. M.; Bennett, H.; Sun, W.; Peters, E.; Makowski, M.; Albert, J.; Cross, K.; Buchanan, W.; Pikaart-Tautges, R.; Ledgerwood, J. E.; Graham, B. S.; Beigel, J. H. An MRNA Vaccine against SARS-CoV-2 — Preliminary Report. *N. Engl. J. Med.* **2020**, *0* (0), NEJMoa2022483. https://doi.org/10.1056/NEJMoa2022483.

(60) Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; Gong, X.; Lou, X.; Shi, W.; Wu, D.; Zhang, H.; Zhu, L.; Deng, W.; Li, Y.; Lu, J.; Li, C.; Wang, X.; Yin, W.; Zhang, Y.; Qin, C. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. *Science* **2020**, *369* (6499), 77–81. https://doi.org/10.1126/science.abc1932.

(61) Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; Chen, X.; Hu, Y.; Liu, X.; Jiang, C.; Li, J.; Yang, M.; Song, Y.; Wang, X.; Gao, Q.; Zhu, F. Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18–59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial. *Lancet Infect. Dis.* **2021**, *21* (2), 181–192. https://doi.org/https://doi.org/10.1016/S1473-3099(20)30843-4.

(62) Smith, T. R. F.; Patel, A.; Ramos, S.; Elwood, D.; Zhu, X.; Yan, J.; Gary, E. N.; Walker, S. N.; Schultheis, K.; Purwar, M.; Xu, Z.; Walters, J.; Bhojnagarwala, P.; Yang, M.;

Chokkalingam, N.; Pezzoli, P.; Parzych, E.; Reuschel, E. L.; Doan, A.; Tursi, N.; Vasquez, M.; Choi, J.; Tello-Ruiz, E.; Maricic, I.; Bah, M. A.; Wu, Y.; Amante, D.; Park, D. H.; Dia, Y.; Ali, A. R.; Zaidi, F. I.; Generotti, A.; Kim, K. Y.; Herring, T. A.; Reeder, S.; Andrade, V. M.; Buttigieg, K.; Zhao, G.; Wu, J.-M.; Li, D.; Bao, L.; Liu, J.; Deng, W.; Qin, C.; Brown, A. S.; Khoshnejad, M.; Wang, N.; Chu, J.; Wrapp, D.; McLellan, J. S.; Muthumani, K.; Wang, B.; Carroll, M. W.; Kim, J. J.; Boyer, J.; Kulp, D. W.; Humeau, L. M. P. F.; Weiner, D. B.; Broderick, K. E. Immunogenicity of a DNA Vaccine Candidate for COVID-19. *Nat. Commun.* **2020**, *11* (1), 2601. https://doi.org/10.1038/s41467-020-16505-0.

(63) Tebas, P.; Yang, S.; Boyer, J. D.; Reuschel, E. L.; Patel, A.; Christensen-Quick, A.; Andrade, V. M.; Morrow, M. P.; Kraynyak, K.; Agnes, J.; Purwar, M.; Sylvester, A.; Pawlicki, J.; Gillespie, E.; Maricic, I.; Zaidi, F. I.; Kim, K. Y.; Dia, Y.; Frase, D.; Pezzoli, P.; Schultheis, K.; Smith, T. R. F.; Ramos, S. J.; McMullan, T.; Buttigieg, K.; Carroll, M. W.; Ervin, J.; Diehl, M. C.; Blackwood, E.; Mammen, M. P.; Lee, J.; Dallas, M. J.; Brown, A. S.; Shea, J. E.; Kim, J. J.; Weiner, D. B.; Broderick, K. E.; Humeau, L. M. Safety and Immunogenicity of INO-4800 DNA Vaccine against SARS-CoV-2: A Preliminary Report of an Open-Label, Phase 1 Clinical Trial. *EClinicalMedicine* **2021**, *31*, 100689. https://doi.org/https://doi.org/10.1016/j.eclinm.2020.100689.

(64) Sahin, U.; Muik, A.; Vogler, I.; Derhovanessian, E.; Kranz, L. M.; Vormehr, M.; Quandt, J.; Bidmon, N.; Ulges, A.; Baum, A.; Pascal, K.; Maurus, D.; Brachtendorf, S.; Lörks, V.; Sikorski, J.; Koch, P.; Hilker, R.; Becker, D.; Eller, A.-K.; Grützner, J.; Tonigold, M.; Boesler, C.; Rosenbaum, C.; Heesen, L.; Kühnle, M.-C.; Poran, A.; Dong, J. Z.; Luxemburger, U.; Kemmer-Brück, A.; Langer, D.; Bexon, M.; Bolte, S.; Palanche, T.; Schultz, A.; Baumann, S.; Mahiny, A. J.; Boros, G.; Reinholz, J.; Szabó, G. T.; Karikó, K.; Shi, P.-Y.; Fontes-Garfias, C.; Perez, J. L.; Cutler, M.; Cooper, D.; Kyratsous, C. A.; Dormitzer, P. R.; Jansen, K. U.; Türeci, Ö. BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in Humans. *medRxiv* **2020**, 2020.12.09.20245175. https://doi.org/10.1101/2020.12.09.20245175.

(65) Vogel, A. B.; Kanevsky, I.; Che, Y.; Swanson, K. A.; Muik, A.; Vormehr, M.; Kranz, L. M.; Walzer, K. C.; Hein, S.; Güler, A.; Loschko, J.; Maddur, M. S.; Ota-Setlik, A.; Tompkins, K.; Cole, J.; Lui, B. G.; Ziegenhals, T.; Plaschke, A.; Eisel, D.; Dany, S. C.; Fesser, S.; Erbar, S.; Bates, F.; Schneider, D.; Jesionek, B.; Sänger, B.; Wallisch, A.-K.; Feuchter, Y.; Junginger, H.; Krumm, S. A.; Heinen, A. P.; Adams-Quack, P.; Schlereth, J.; Schille, S.; Kröner, C.; de la Caridad Güimil Garcia, R.; Hiller, T.; Fischer, L.; Sellers, R. S.; Choudhary, S.; Gonzalez, O.; Vascotto, F.; Gutman, M. R.; Fontenot, J. A.; Hall-Ursone, S.; Brasky, K.; Griffor, M. C.; Han, S.; Su, A. A. H.; Lees, J. A.; Nedoma, N. L.; Mashalidis, E. H.; Sahasrabudhe, P. V; Tan, C. Y.; Pavliakova, D.; Singh, G.; Fontes-Garfias, C.; Pride, M.; Scully, I. L.; Ciolino, T.; Obregon, J.; Gazi, M.; Carrion, R.; Alfson, K. J.; Kalina, W. V; Kaushal, D.; Shi, P.-Y.; Klamp, T.; Rosenbaum, C.; Kuhn, A. N.; Türeci, Ö.; Dormitzer, P. R.; Jansen, K. U.; Sahin, U. BNT162b Vaccines Are Immunogenic and Protect Non-Human Primates against SARS-CoV-2. *bioRxiv* **2020**, 2020.12.11.421008. https://doi.org/10.1101/2020.12.11.421008.

(66) Keech, C.; Albert, G.; Cho, I.; Robertson, A.; Reed, P.; Neal, S.; Plested, J. S.; Zhu, M.; Cloney-Clark, S.; Zhou, H.; Smith, G.; Patel, N.; Frieman, M. B.; Haupt, R. E.; Logue, J.; McGrath, M.; Weston, S.; Piedra, P. A.; Desai, C.; Callahan, K.; Lewis, M.; Price-Abbott, P.; Formica, N.; Shinde, V.; Fries, L.; Lickliter, J. D.; Griffin, P.; Wilkinson, B.; Glenn, G. M. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *N. Engl. J. Med.* **2020**, *383* (24), 2320–2332.

https://doi.org/10.1056/NEJMoa2026920.

(67)   Tian, J.-H.; Patel, N.; Haupt, R.; Zhou, H.; Weston, S.; Hammond, H.; Logue, J.; Portnoff, A. D.; Norton, J.; Guebre-Xabier, M.; Zhou, B.; Jacobson, K.; Maciejewski, S.; Khatoon, R.; Wisniewska, M.; Moffitt, W.; Kluepfel-Stahl, S.; Ekechukwu, B.; Papin, J.; Boddapati, S.; Jason Wong, C.; Piedra, P. A.; Frieman, M. B.; Massare, M. J.; Fries, L.; Bengtsson, K. L.; Stertman, L.; Ellingsworth, L.; Glenn, G.; Smith, G. SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice. *Nat. Commun.* **2021**, *12* (1), 372. https://doi.org/10.1038/s41467-020-20653-8.

(68)   van Doremalen, N.; Lambe, T.; Spencer, A.; Belij-Rammerstorfer, S.; Purushotham, J. N.; Port, J. R.; Avanzato, V.; Bushmaker, T.; Flaxman, A.; Ulaszewska, M.; Feldmann, F.; Allen, E. R.; Sharpe, H.; Schulz, J.; Holbrook, M.; Okumura, A.; Meade-White, K.; Pérez-Pérez, L.; Bissett, C.; Gilbride, C.; Williamson, B. N.; Rosenke, R.; Long, D.; Ishwarbhai, A.; Kailath, R.; Rose, L.; Morris, S.; Powers, C.; Lovaglio, J.; Hanley, P. W.; Scott, D.; Saturday, G.; de Wit, E.; Gilbert, S. C.; Munster, V. J. ChAdOx1 NCoV-19 Vaccination Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques. *bioRxiv* **2020**, 10.1101/2020.05.13.093195. https://doi.org/10.1101/2020.05.13.093195.

(69)   Folegatti, P. M.; Ewer, K. J.; Aley, P. K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E. A.; Dold, C.; Faust, S. N.; Finn, A.; Flaxman, A. L.; Hallis, B.; Heath, P.; Jenkin, D.; Lazarus, R.; Makinson, R.; Minassian, A. M.; Pollock, K. M.; Ramasamy, M.; Robinson, H.; Snape, M.; Tarrant, R.; Voysey, M.; Green, C.; Douglas, A. D.; Hill, A. V. S.; Lambe, T.; Gilbert, S. C.; Pollard, A. J.; Aboagye, J.; Adams, K.; Ali, A.; Allen, E.; Allison, J. L.; Anslow, R.; Arbe-Barnes, E. H.; Babbage, G.; Baillie, K.; Baker, M.; Baker, N.; Baker, P.; Baleanu, I.; Ballaminut, J.; Barnes, E.; Barrett, J.; Bates, L.; Batten, A.; Beadon, K.; Beckley, R.; Berrie, E.; Berry, L.; Beveridge, A.; Bewley, K. R.; Bijker, E. M.; Bingham, T.; Blackwell, L.; Blundell, C. L.; Bolam, E.; Boland, E.; Borthwick, N.; Bower, T.; Boyd, A.; Brenner, T.; Bright, P. D.; Brown-O'Sullivan, C.; Brunt, E.; Burbage, J.; Burge, S.; Buttigieg, K. R.; Byard, N.; Cabera Puig, I.; Calvert, A.; Camara, S.; Cao, M.; Cappuccini, F.; Carr, M.; Carroll, M. W.; Carter, V.; Cathie, K.; Challis, R. J.; Charlton, S.; Chelysheva, I.; Cho, J.-S.; Cicconi, P.; Cifuentes, L.; Clark, H.; Clark, E.; Cole, T.; Colin-Jones, R.; Conlon, C. P.; Cook, A.; Coombes, N. S.; Cooper, R.; Cosgrove, C. A.; Coy, K.; Crocker, W. E. M.; Cunningham, C. J.; Damratoski, B. E.; Dando, L.; Datoo, M. S.; Davies, H.; De Graaf, H.; Demissie, T.; Di Maso, C.; Dietrich, I.; Dong, T.; Donnellan, F. R.; Douglas, N.; Downing, C.; Drake, J.; Drake-Brockman, R.; Drury, R. E.; Dunachie, S. J.; Edwards, N. J.; Edwards, F. D. L.; Edwards, C. J.; Elias, S. C.; Elmore, M. J.; Emary, K. R. W.; English, M. R.; Fagerbrink, S.; Felle, S.; Feng, S.; Field, S.; Fixmer, C.; Fletcher, C.; Ford, K. J.; Fowler, J.; Fox, P.; Francis, E.; Frater, J.; Furze, J.; Fuskova, M.; Galiza, E.; Gbesemete, D.; Gilbride, C.; Godwin, K.; Gorini, G.; Goulston, L.; Grabau, C.; Gracie, L.; Gray, Z.; Guthrie, L. B.; Hackett, M.; Halwe, S.; Hamilton, E.; Hamlyn, J.; Hanumunthadu, B.; Harding, I.; Harris, S. A.; Harris, A.; Harrison, D.; Harrison, C.; Hart, T. C.; Haskell, L.; Hawkins, S.; Head, I.; Henry, J. A.; Hill, J.; Hodgson, S. H. C.; Hou, M. M.; Howe, E.; Howell, N.; Hutlin, C.; Ikram, S.; Isitt, C.; Iveson, P.; Jackson, S.; Jackson, F.; James, S. W.; Jenkins, M.; Jones, E.; Jones, K.; Jones, C. E.; Jones, B.; Kailath, R.; Karampatsas, K.; Keen, J.; Kelly, S.; Kelly, D.; Kerr, D.; Kerridge, S.; Khan, L.; Khan, U.; Killen, A.; Kinch, J.; King, T. B.; King, L.; King, J.; Kingham-Page, L.; Klenerman, P.; Knapper, F.; Knight, J. C.; Knott, D.; Koleva, S.; Kupke, A.; Larkworthy, C. W.; Larwood, J. P. J.; Laskey, A.; Lawrie, A.

M.; Lee, A.; Ngan Lee, K. Y.; Lees, E. A.; Legge, H.; Lelliott, A.; Lemm, N.-M.; Lias, A. M.; Linder, A.; Lipworth, S.; Liu, X.; Liu, S.; Lopez Ramon, R.; Lwin, M.; Mabesa, F.; Madhavan, M.; Mallett, G.; Mansatta, K.; Marcal, I.; Marinou, S.; Marlow, E.; Marshall, J. L.; Martin, J.; McEwan, J.; McInroy, L.; Meddaugh, G.; Mentzer, A. J.; Mirtorabi, N.; Moore, M.; Moran, E.; Morey, E.; Morgan, V.; Morris, S. J.; Morrison, H.; Morshead, G.; Morter, R.; Mujadidi, Y. F.; Muller, J.; Munera-Huertas, T.; Munro, C.; Munro, A.; Murphy, S.; Munster, V. J.; Mweu, P.; Noé, A.; Nugent, F. L.; Nuthall, E.; O'Brien, K.; O'Connor, D.; Oguti, B.; Oliver, J. L.; Oliveira, C.; O'Reilly, P. J.; Osborn, M.; Osborne, P.; Owen, C.; Owens, D.; Owino, N.; Pacurar, M.; Parker, K.; Parracho, H.; Patrick-Smith, M.; Payne, V.; Pearce, J.; Peng, Y.; Peralta Alvarez, M. P.; Perring, J.; Pfafferott, K.; Pipini, D.; Plested, E.; Pluess-Hall, H.; Pollock, K.; Poulton, I.; Presland, L.; Provstgaard-Morys, S.; Pulido, D.; Radia, K.; Ramos Lopez, F.; Rand, J.; Ratcliffe, H.; Rawlinson, T.; Rhead, S.; Riddell, A.; Ritchie, A. J.; Roberts, H.; Robson, J.; Roche, S.; Rohde, C.; Rollier, C. S.; Romani, R.; Rudiansyah, I.; Saich, S.; Sajjad, S.; Salvador, S.; Sanchez Riera, L.; Sanders, H.; Sanders, K.; Sapaun, S.; Sayce, C.; Schofield, E.; Screaton, G.; Selby, B.; Semple, C.; Sharpe, H. R.; Shaik, I.; Shea, A.; Shelton, H.; Silk, S.; Silva-Reyes, L.; Skelly, D. T.; Smee, H.; Smith, C. C.; Smith, D. J.; Song, R.; Spencer, A. J.; Stafford, E.; Steele, A.; Stefanova, E.; Stockdale, L.; Szigeti, A.; Tahiri-Alaoui, A.; Tait, M.; Talbot, H.; Tanner, R.; Taylor, I. J.; Taylor, V.; Te Water Naude, R.; Thakur, N.; Themistocleous, Y.; Themistocleous, A.; Thomas, M.; Thomas, T. M.; Thompson, A.; Thomson-Hill, S.; Tomlins, J.; Tonks, S.; Towner, J.; Tran, N.; Tree, J. A.; Truby, A.; Turkentine, K.; Turner, C.; Turner, N.; Turner, S.; Tuthill, T.; Ulaszewska, M.; Varughese, R.; Van Doremalen, N.; Veighey, K.; Verheul, M. K.; Vichos, I.; Vitale, E.; Walker, L.; Watson, M. E. E.; Welham, B.; Wheat, J.; White, C.; White, R.; Worth, A. T.; Wright, D.; Wright, S.; Yao, X. L.; Yau, Y. Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial. *Lancet* **2020**, *396* (10249), 467–478. https://doi.org/https://doi.org/10.1016/S0140-6736(20)31604-4.

(70) Bos, R.; Rutten, L.; van der Lubbe, J. E. M.; Bakkers, M. J. G.; Hardenberg, G.; Wegmann, F.; Zuijdgeest, D.; de Wilde, A. H.; Koornneef, A.; Verwilligen, A.; van Manen, D.; Kwaks, T.; Vogels, R.; Dalebout, T. J.; Myeni, S. K.; Kikkert, M.; Snijder, E. J.; Li, Z.; Barouch, D. H.; Vellinga, J.; Langedijk, J. P. M.; Zahn, R. C.; Custers, J.; Schuitemaker, H. Ad26-Vector Based COVID-19 Vaccine Encoding a Prefusion Stabilized SARS-CoV-2 Spike Immunogen Induces Potent Humoral and Cellular Immune Responses. *bioRxiv* **2020**, 2020.07.30.227470. https://doi.org/10.1101/2020.07.30.227470.

(71) Sadoff, J.; Gars, M. Le; Shukarev, G.; Heerwegh, D.; Truyers, C.; de Groot, A. M.; Stoop, J.; Tete, S.; Van Damme, W.; Leroux-Roels, I.; Berghmans, P.-J.; Kimmel, M.; Van Damme, P.; de Hoon, J.; Smith, W.; Stephenson, K. E.; Barouch, D. H.; De Rosa, S. C.; Cohen, K. W.; McElrath, M. J.; Cormier, E.; Scheper, G.; Hendriks, J.; Struyf, F.; Douoguih, M.; Van Hoof, J.; Schuitemaker, H. Safety and Immunogenicity of the Ad26.COV2.S COVID-19 Vaccine Candidate: Interim Results of a Phase 1/2a, Double-Blind, Randomized, Placebo-Controlled Trial. *medRxiv* **2020**, 2020.09.23.20199604. https://doi.org/10.1101/2020.09.23.20199604.

(72) de Jonge, J.; van Dijken, H.; de Heij, F.; Spijkers, S.; Mouthaan, J.; de Jong, R.; Roholl, P.; Adami, E. A.; Akamatsu, M. A.; Ho, P. L.; Brunner, L.; Collin, N.; Friede, M.; Ferreira, J. A.; Luytjes, W. H7N9 Influenza Split Vaccine with SWE Oil-in-Water

Adjuvant Greatly Enhances Cross-Reactive Humoral Immunity and Protection against Severe Pneumonia in Ferrets. *npj Vaccines* **2020**, *5* (1), 38. https://doi.org/10.1038/s41541-020-0187-4.

(73) Gerrish, P. J.; Saldaña, F.; Galeota-Sprung, B.; Colato, A.; Rodriguez, E. E.; Hernández, J. X. V. How Unequal Vaccine Distribution Promotes the Evolution of Vaccine Escape. *medRxiv* **2021**, 2021.03.27.21254453. https://doi.org/10.1101/2021.03.27.21254453.

(74) Yuan, M.; Wu, N. C.; Zhu, X.; Lee, C.-C. D.; So, R. T. Y.; Lv, H.; Mok, C. K. P.; Wilson, I. A. A Highly Conserved Cryptic Epitope in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV. *Science* **2020**, *368* (6491), 630–633. https://doi.org/10.1126/science.abb7269.

(75) Wibmer, C. K.; Ayres, F.; Hermanus, T.; Madzivhandila, M.; Kgagudi, P.; Lambson, B. E.; Vermeulen, M.; van den Berg, K.; Rossouw, T.; Boswell, M.; Ueckermann, V.; Meiring, S.; von Gottberg, A.; Cohen, C.; Morris, L.; Bhiman, J. N.; Moore, P. L. SARS-CoV-2 501Y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma. *bioRxiv Prepr. Serv. Biol.* **2021**, 10.1101/2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166.

(76) Wang, P.; Nair, M. S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P. D.; Graham, B. S.; Mascola, J. R.; Chang, J. Y.; Yin, M. T.; Sobieszczyk, M.; Kyratsous, C. A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D. D. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *bioRxiv* **2021**, 2021.01.25.428137. https://doi.org/10.1101/2021.01.25.428137.

(77) Yadav, P.; Sapkal, G. N.; Abraham, P.; Ella, R.; Deshpande, G.; Patil, D. Y.; Nyayanit, D.; Gupta, N.; Sahay, R. R.; Shete, A. M.; Panda, S.; Bhargava, B.; Mohan, V. K. Neutralization of Variant under Investigation B.1.617 with Sera of BBV152 Vaccinees. *bioRxiv* **2021**, 2021.04.23.441101. https://doi.org/10.1101/2021.04.23.441101.

(78) Zhang, Y.-N.; Paynter, J.; Fourfouris, T.; Sou, C.; Ngo, T.; He, L.; Zhu, J. Mechanism of a COVID-19 Nanoparticle Vaccine Candidate That Elicits a Broadly Neutralizing Antibody Response to SARS-CoV-2 Variants. *bioRxiv* **2021**, 2021.03.26.437274. https://doi.org/10.1101/2021.03.26.437274.

(79) Bachmann, M. F.; Zinkernagel, R. M. Neutralizing Antiviral B Cell Responses. *Annu. Rev. Immunol.* **1997**, *15* (1), 235–270. https://doi.org/10.1146/annurev.immunol.15.1.235.

(80) Percie du Sert, N.; Hurst, V.; Ahluwalia, A.; Alam, S.; Avey, M. T.; Baker, M.; Browne, W. J.; Clark, A.; Cuthill, I. C.; Dirnagl, U.; Emerson, M.; Garner, P.; Holgate, S. T.; Howells, D. W.; Karp, N. A.; Lazic, S. E.; Lidster, K.; MacCallum, C. J.; Macleod, M.; Pearl, E. J.; Petersen, O. H.; Rawle, F.; Reynolds, P.; Rooney, K.; Sena, E. S.; Silberberg, S. D.; Steckler, T.; Würbel, H. The ARRIVE Guidelines 2.0: Updated Guidelines for Reporting Animal Research. *PLOS Biol.* **2020**, *18* (7), e3000410.

(81) Osterrieder, N.; Bertzbach, L. D.; Dietert, K.; Abdelgawad, A.; Vladimirova, D.; Kunec, D.; Hoffmann, D.; Beer, M.; Gruber, A. D.; Trimpert, J. Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. *Viruses* **2020**, *12* (7). https://doi.org/10.3390/v12070779.

Table of Contents (TOC)/Abstract Graphic